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ABSTRACT 
 
Background:  Serum free light chains (FLC) are associated with imbalances in heavy and light 
chain production. Abnormal FLC ratios have been associated with risk of progression in certain 
diseases. Automated assays are available for their determination and they are used in the follow-
up and management of patients with monoclonal gammopathies. Acceptable imprecision, 
specificity, accuracy and reproducibility between reagent batches is required to prevent under- or 
overestimation. Method validation is a standard process in every good laboratory to judge the 
acceptability of a new method.  Reference intervals have been established in an older population, 
but it was considered important to verify these in our population. HIV is associated with B-cell 
dysfunction. As B-cell abnormalities are associated with disorders leading to monoclonal 
gammopathies, we postulated that the FLC levels and FLC ratio would be abnormal in HIV 
infected individuals. 
 
Methods and materials: Controls and pooled patient samples were used for the method validation 
study which included imprecision studies, linearity, recovery and interference studies, and 
method comparison studies, the latter compared our method to the same method used in another 
laboratory. For the reference interval study, blood was obtained from 120 healthy subjects. The 
following blood tests were performed: total protein, IgG, IgA, IgM, creatinine, protein 
electrophoresis, kappa FLC and lambda FLC. Using the kappa and lambda FLC results, a FLC 
ratio was determined. Three hundred and sixty-nine HIV positive subjects were then studied. The 
same tests were performed, as well as CD4+ counts and viral loads on the majority of them. 
 
Results: For the method validation study, precision, linearity and recovery was acceptable. 
Minimal interference was observed with haemolysis, lipaemia, bilirubin and rheumatoid factor. 
Our method showed comparable performance with the established method. For the reference 
interval study, all the creatinine values were normal, as were serum protein values. The serum 
protein electrophoreses were independently reviewed by 3 pathologists. Most were normal, with 
a few polyclonal increases seen, but no definite monoclonal bands. The 95% reference intervals 
for FLC’s as well as the FLC ratio were not statistically significantly different to the 
manufacturer’s recommendations. When examining the HIV positive study population, we found 
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that FLC and FLC ratio were influenced by markers of HIV disease severity, such as CD4+ 
count, IgG, viral load, use of antiretroviral treatment and abnormal serum protein 
electrophoreses. 
 
Conclusion: The validation study of FLC showed excellent precision, acceptable bias, good 
linearity, good recovery and minimal interference, allowing routine introduction of the test. The 
95% reference intervals obtained for our population were slightly higher than those 
recommended by the manufacturer. However, as most of the values fell within the 
manufacturer’s limits, we could accept the manufacturer’s recommended cut-offs. We found that 
FLC levels were definitely influenced by markers of HIV disease severity in our population and 
we postulate that they may be of use for follow-up of patients with HIV. 
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ABSTRAK 
 
Agtergrond:  Serum vry ligte kettings (VLK) word geassosieer met ‘n wanbalans van ligte en 
swaar ketting produksie. Abnormale VLK ratios is geassosieer met ‘n risiko van verloop in 
sekere siektes. Geoutomatiseerde laboratorium toetse vir VLK is beskikbaar  vir hul bepaling en 
word gebruik om pasiënte met monoklonale gammopatieë op te volg en te behandel. 
Aanvaarbare impresisie, spesifisiteit, akkuraatheid en herhaalbaarheid tussen reagens besendings 
is belangrik om onder- of oorbepaling te verhoed. Metode validasie is ’n standaard proses in elke 
goeie laboratorium om die aanvaarbaarheid van ’n nuwe metode te bepaal. Verwysingswaardes 
is al bepaal in ’n ouer populasie. Ons het besluit om die verwysingswaardes in ons populasie te 
bepaal. Mens-immuungebrekvirus (MIV) word geassosieer met B-sel disfunksie.  Omdat B-sel 
abnormaliteite geassosieer word met afwykings wat tot monoklonale gammopatieë lei, het ons 
gepostuleer dat die VLK vlakke en VLK ratio abnormaal sal wees in MIV geïnfekteerde persone. 
 
Metodes en Materiale:  Kontroles en pasiënt monsters is gebruik vir die metode validasie studie 
wat impresisie studies,  lineariteit, herwinning, inmenging en metode korrelasie studies ingesluit 
het. In laasgenoemde geval is ons metode met dieselfde metode  van ’n ander laboratorium 
vergelyk. Vir die verwysingswaardes studie is 120 gesonde persone se bloed gebruik. Die 
volgende toetse is bepaal: totale proteïen, IgG, IgA, IgM, kreatinien, proteïen elektroferese, 
kappa en lambda VLK. Die VLK ratio is bepaal deur die kappa en lambda resultate te gebruik. 
Driehonderd nege en sestig MIV-positiewe pasiente is gebruik vir die studie. Dieselfde toetse 
was gedoen, asook CD4+ tellings en virale ladings op die meerderheid van pasiente. 
 
Resultate: Vir die metode validasie studie, was presisie, lineariteit en herwinning aanvaarbaar. 
Minimale inmenging van hemolise, lipemie, bilirubien en rumatoïede factor is waargeneem. Ons 
metode het goed gekorreleer met die bepaalde metode. Die serum kreatinien en serum totale 
proteïen waardes was normaal tydens die verwysingswaardes studie.  Die serum proteïen 
elektroferese was onafhanklik beoordeel deur 3 patoloë.  Die  meeste was normaal met enkele 
poliklonale verhogings, maar geen definitiewe monoklonale bande nie.  Die 95% verwysings 
intervalle vir VLK en VLK ratio het nie statisties betekenisvol verskil van die vervaardiger se 
aanbevelings nie. In die studie van die MIV-positiewe studie populasie, het ons gevind dat VLK 
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en VLK ratio beïnvloed word deur merkers van ernstige MIV siekte, soos CD4+ telling, IgG, 
virale lading, die gebruik van antiretrovale medikasie en abnormale serum proteïen elektroferese. 
 
Gevolgtrekking: Die validasie studie van VLK het uitstekende presisie, aanvaarbare 
partydigheid, goeie lineariteit, goeie herwinning en minimale inmenging gewys, wat die roetine 
instelling van die toets toegelaat het. Die 95% verwysingsintervalle wat vir ons populasie bepaal 
is, was effens hoër as die vervaardiger se aanbeveling. Die meeste van die waardes het egter 
binne die vervaardiger se limiete geval, dus kon ons die vervaardiger se afsnypunte aanvaar. Ons 
het gevind dat VLK vlakke definitief beïnvloed word deur merkers van die ernstigheidsgraad van 
MIV siekte in ons populasie en ons postuleer dat VLK van waarde kan wees met die opvolg van 
MIV pasiente. 
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INTRODUCTION 
 
Human Immunodeficiency Virus (HIV) is a retrovirus belonging to the genus Lentiviruses.  
Currently, HIV infection is a worldwide epidemic.  In poor countries with a high prevalence of HIV, 
such as South Africa, with an estimated 5.3 million people living with HIV/Acquired 
Immunodeficiency Syndrome (AIDS), the cost implication of unnecessary investigation of patients 
may have a significant impact on health care spending and allocation of resources (Abdool Karim et 
al. 2009). South Africa is facing an enormous challenge with its HIV and tuberculosis (TB) 
epidemics. Today there are an estimated 38 million people living with HIV or AIDS and over 5 
million of those people are living in South Africa. This is the highest percentage of people in any 
single country that is HIV positive, according to a study done by the United Nations in 2010. The 
previous count made in 2009 of Eastern and Southern Africa points to 7.7 million people in need of 
antiretroviral therapy (ART); and the estimated number receiving treatment are 3.2 million, which is 
a mere 41% (www.unaids.org). 
 
Infection with HIV is associated with a gradual decline of CD4+ T-cells as well as several B-cell 
abnormalities. The latter includes polyclonal activation, hypergammaglobulinaemia, auto-immune 
phenomena, defective response to antigen stimulation and the occurrence of AIDS-related 
lymphomas (De Milito. 2004).  Monoclonal proteins have also been noted with increased frequency 
on serum protein electrophoresis in patients with HIV (Heriot K et al. 1985). This and the association 
of HIV with non-Hodgkins lymphoma (NHL) may be due to B-cell dysfunction in these patients. 
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SECTION I: LITERATURE REVIEW 
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1.1 HIV INFECTION 
 
The HIV virus targets the immune system by attacking CD4+ T-cells. The virus inserts its 
genetic material into the CD4+ T-cell’s DNA and replicates. The host CD4+ T-cells 
eventually die and the body’s ability to defend itself against disease decreases until 
eventually, the CD4+ T-cells decrease to such an extent, that the patient develops AIDS.  
The virus copies its genetic material into the CD4+ T-cells with an increasing level of 
error. Thus the HIV replicates with a high rate and mutates at a high speed. Additionally, 
the envelope that contained the HIV particle consists of the same material as human cells, 
thus making it difficult for the immune system to distinguish between virus particles and 
healthy cells (www.news.bbc.co.uk). 
 
HIV infection can be divided into 3 different phases as shown in figure 1.1: 
 
1. The acute phase 
 
The acute phase of HIV occurs six to twelve weeks after infection and lasts until anti-
HIV antibodies are detectable in the blood. HIV infection is characterized by a 
deterioration of the cellular immune system with a steady decrease in CD4+ T-cells 
leading to various clinical symptoms (Vergis et al. 2000).  The loss of CD4+ T-cells 
correlates with viral load. The degree of immunodeficiency associated with HIV infection 
correlates with CD4+ T-cell counts and absolute CD4+ counts are used to determine when 
to initiate highly active antiretroviral treatment (HAART). Recently it has been reported 
that the majority of this memory CD4+ T-cell loss occurs in the gastrointestinal tract in 
the first few weeks after infection, as this is where 80% of the CD4+ T-cell population is 
found (Brenchley et al. 2004). These CD4+ T-cells express the CCR5 HIV coreceptors 
which enable entry of HIV into the host cell. The loss of gut memory T-cells leads to loss 
of mucosal integrity and microbial translocation to the systemic circulation (Douek D. 
2007). This results in chronic immune activation, which is believed to contribute further 
to the progressive depletion of the remaining CD4+ T-cells (Smith S. 2006; Appay and 
Sauce 2008; Virgin and Walker. 2010). Immune activation in chronic HIV infection 
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includes polyclonal B cell activation, increased T-cell turnover, increased activated T-
cells and increased cytokines and other inflammatory mediators. This can help with 
restoration of memory CD4+ T-cells and immunocompetence, but unfortunately also 
leads to lymph node fibrosis, retention of effector T-cell in lymph nodes, thymic 
dysfunction, clonal exhaustion, drainage of memory T-cell pools, and generation of more 
targets for HIV to permit ongoing HIV replication (Douek D. 2007; Sodora and Silvestri. 
2008). 
 
2. The latent period 
The immune response to the infection is able to control viral replication to a certain 
extent and viral particles decrease in the blood stream.  The patient enters a clinically 
asymptomatic (or latent) phase with only few viral particles detectable in the bloodstream 
or peripheral blood lymphocytes  and the CD4+ count is only slightly decreased.  During 
the latent phase, there may be no clinical manifestations, except for a generalized 
lymphadenopathy. The lymphoid tissue serves as a major reservoir for HIV, with the 
follicular dendritic cells in this tissue filtering and trapping free virus and infected CD4+ 
T-cells. This leads to disruption of the lymph node architecture and release of HIV 
(Douek. 2007; Brenchley et al. 2004; Swingler et al. 2008). 
 
3. Onset of disease – AIDS 
This occurs between 3-15 years after initial infection. The virus can no longer be 
controlled as CD4+ T-cells are destroyed and leads to loss of immune competence. 
The humoral immunity also decreases with B-cells exhibiting an increase in markers of 
activation and proliferation. (Moir et al. 2004; Swingler et al. 2008). These B-cells 
undergo terminal differentiation leading to an increase in immunoglobulin secretion and 
polyclonal hypergammaglobulinaemia. However, these antibodies are nonspecific, which 
explains why the patients are still at risk of bacterial infections (Moir et al 2001). 
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autoantibodies (Shirai et al. 1992; Haynes et al. 2005; Ng et al. 1996; Moir et al. 2008; de 
Milito. 2004) and an increase in the frequency  of B-cell malignancies ( Martinez Maza et 
al. 2002; Moir et al. 2008). Monoclonal proteins have also been noted with increased 
frequency on serum protein electrophoresis in patients with HIV (Jansen van Vuuren et 
al. 2010). 
 
A probable cause of abnormal clonal B-lymphocyte proliferation in patients with HIV 
infection is the hyperstimulated state where more B-cells spontaneously secrete 
immunoglobulins and fewer B-cells are in the resting state (Lane et al. 1983; Caggi et al. 
2008). There are several possible causes for this polyclonal B-cell activation. Firstly, 
certain infections in healthy people may result in the development of paraproteins 
because of hyperstimulation and subsequent immunoglobulin production. HIV infected 
patients have other infective processes that resulted in higher immunoglobulin 
production, but may not be detected clinically (Schnittmann et al. 1986). HIV infected 
patients are known to have a higher incidence of infections due to certain viruses, 
including Epstein-Barr virus (EBV), herpes virus, hepatitis B virus and cytomegalovirus 
(CMV). These DNA viruses are capable of inducing B-cell activation (Schnittmann et al. 
1986). Secondly, B-cell activation may be secondary to alteration of regulatory T-cell 
influences (de Milito. 2004; Caggi et al. 2008). Thirdly, B-cell activation in HIV 
infection may result from the virus actually infecting B-cells and acting as a polyclonal 
activator, analogous to EBV infection of B-cells (Schnittmann et al. 1986). This has 
recently been shown to occur in vitro. An autonomous clone could arise from virus-
activated B-cells if there was integration of the virus near a genetic enhancer element or a 
proto-oncogene which would induce cellular transformation (Crapper et al. 1987). 
 
HIV–induced immune dysfunction is not only related to B-cells, but also to other 
components of the immune system such as the low CD4+ T-cells with the loss of immune 
function (Lane et al. 1983). In untreated patients, HIV infection leads to chronic immune 
activation through indirect systemic effects or bystander effects of ongoing replication. 
Bystander effects have been described for CD4+, CD8+ T-cell, natural killer (NK) cells 
and B-cells (Grossman et al. 2006; Sodora and Silvestri. 2008; Moir and Fauci. 2009). 
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In healthy individuals most B-cells in the periphery are resting naïve B-cells or memory 
B-cells expressing either switched or unswitched antibody isotypes (IgG, IgE and IgA, or 
IgM and IgD respectively)( Moir and Fauci. 2009). In HIV infected patients, several 
additional B-cell subpopulations, which are not normally present in the peripheral blood 
of uninfected individuals, can make up significant fractions of the total B-cell population 
including: immature transitional B-cells, exhausted B-cells, activated mature B-cells and 
plasmablasts (Moir and Fauci. 2009). 
 
The effects of ongoing HIV replication on B-cells are thought to reflect a combination of 
direct interactions of B-cells with the virus and indirect interactions that are associated 
with a wide range of systemic alterations (Moir and Fauci. 2009). Direct interactions 
between HIV and B-cells were reported years ago, although there is little evidence that 
HIV can productively replicate in B-cells in vivo (Schnittman et al. 1986). There is 
evidence that HIV binds to B-cells in vivo via the complement receptor CD21(Moir and 
Fauci. 2009), which is expressed on most mature B-cells and complement proteins bound 
to HIV virions that circulate in vivo (Kacani et al. 2000; Moir et al. 2000). These 
immune-complex-based interactions might provide stimulating signals to B-cells, 
although this is of low frequency. This B-cell-HIV virion interaction most likely 
facilitates cell-to-cell transmission of HIV (Malaspina et al. 2002). A similar mechanism 
of HIV interaction has been suggested for follicular dendritic cells which also express 
CD21 and might function as a long-lived extracellular reservoir for HIV even in the 
presence of effective ART (Rappocciolo et al. 2006).  
 
Several cytokines and growth factors have been suggested to directly or indirectly trigger 
the activation of B-cells in HIV patients, namely interferon-α (IFN) (Mandl et al. 2008), 
tumour necrosis factor (TNF) (Rieckman et al. 1991), interleukin-6(IL 6), IL-10 (Weimer 
et al. 1998), CD10 ligand (Muller et al 1998) and B-cell activating factor (He et al. 2006). 
These factors are increased during HIV infection and are thought to be associated with B-
cell hyperactivation in these patients. 
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Another indirect effect of HIV on B-cells is HIV-induced lymphopaenia. In most 
untreated patients, HIV infection leads to a loss of CD4+ T-cells. T-cell homeostatic 
cytokine IL-7 is dysregulated in HIV-infected patients with advanced HIV-associated 
disease. Increased serum levels of IL-7 were associated with decreased numbers of CD4+ 
T-cells (Rappocciolo et al. 2006: He et al. 2006; Moir and Fauci. 2009).  IL-7 can induce 
the proliferation of human B-cell precursors (Le Bien and Tedder. 2008). A high viral 
load and low CD4+ T-cell counts are thus associated with increased serum levels of IL-7 
and increased numbers of immature transitional B- cells (Malaspina et al. 2006). A 
similar association between increased serum levels of IL-7 (Moir and Fauci. 2008), B-cell 
immaturity and decreased CD4+ T-cell counts was observed in patients with non-HIV-
related idiopathic CD4+ T-cell lymphopaenia, which suggests that HIV-induced CD4+ T-
cell lymphopaenia and not HIV viraemia itself drives the expansion of immature 
transitional B-cells in HIV infected patients (Conge et al. 1998). 
 
The third indirect effect of HIV on B-cells is HIV-associated B- cell exhaustion. The loss 
of CD21 on peripheral blood cells is a reliable marker of ongoing HIV replication and 
disease progression (Moir and Fauci. 2008). CD21low B-cells constitute a heterogeneous 
population of cells in infected HIV patients, one fraction of the CD21low B-cell 
compartment is made up of CD27 B-cells that have undergone HIV-induced activation 
and differentiation to plasmablasts (He et al. 2006) and another fraction is made up of 
immature transitional CD10 B-cells that are over-represented as a result of HIV-induced 
T-cell lymphopaenia (Brenchley et al. 2006).  A large proportion of CD21low B-cells in 
HIV-viraemic patients does not fit into either of these fractions and it is believed that 
these B-cells constitute an exhausted B-cell subpopulation (Moir et al. 2008). Exhausted 
B- cells refers to virus- specific immune cells that have lost their function due to the 
chronic nature of viral infection (Day. 2006; Trautmann et al. 2006; Virgin and Walker 
2010).  
 
There is strong evidence to suggest that memory B-cells are exhausted in the peripheral 
blood of HIV viraemic patients (Moir and Fauci. 2008; Moir and Fauci. 2009; Bussmann 
et al. 2009). As HIV specific responses increase in B-cells that show signs of functional 
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exhaustion, such dysregulation might contribute to the inefficiency of the antibody 
response against HIV in infected patients. Chronic HIV viraemia is associated with the 
expansion of several aberrant B-cell subpopulations including immature transitional, 
hyperactivated and exhausted, which can contribute to various B-cell dysfunctions 
(Ehrhardt et al. 2008; Wherry et al. 2007; Shin and Wherry. 2007). 
 
Some B-cell abnormalities associated with HIV-replication induced immune-cell 
activation can be reversed by ART, whereas others, particularly loss of memory B-cells 
persist, even after several years of effective ART (Morris et al. 1998). The B-cell 
abnormalities that decrease with ART include hypergammaglobulinaemia and HIV-
specific and HIV non- specific B-cell responses as measured by the number of B-cells 
that spontaneously secrete high levels of immunoglobulins (Moir et al. 2001; Notermans 
et al. 2001; Amman et al. 1984; Nilssen et al. 2004).  
 
B-cells of HIV-infected patients express high levels of activation markers and studies 
have shown that these activation markers are normalized by ART (Moir et al. 2004; 
Riekman et al. 1991). One of the consequences of HIV- induced chronic immune cell 
activation is increased cell turnover with cell proliferation and cell death.  Studies have 
shown an increased turnover of CD4+ and CD8+ T-cells, as well as of NK cells and B-
cells during HIV infection.  This increased turnover is reversed by ART (Kovacs et al. 
2001; de Boer et al. 2003).  In most HIV infected individuals, the initiation of ART leads 
to a gradual increase in CD4+ T-cell counts and a decrease in CD8+ T-cell counts 
(Ribeiro. 2007). Several studies have shown that B-cell numbers are decreased in HIV 
infected individuals (Shearer et al. 2000; Meira et al. 2005), however with ART, B-cell 
numbers increase and B-cell dynamics in response to infection are more closely related to 
those of CD4+ rather than CD8+ T- cells (Moir et al. 2008; Le Guillou-Guetemette. 2006). 
An increased rate of B-cell death during viral replication may also contribute to the loss 
of B-cells (Ho et al. 2006; Moir et al. 2004). 
 
Although most B-cell defects in HIV infection can be reversed by ART, one important 
exception is the loss of memory B-cells and the decrease in memory B-cell function (De 
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Milito. 2004; Caggi et al. 2008).  CD27 is a marker that is used to define memory B- 
cells.  Studies have shown that although ART leads to decreased numbers of CD27+ 
activated B-cells and plasmablasts, the increase in number of CD27+ resting memory B-
cells after treatment occurs slowly and remains incomplete. (Moir et al. 2008; Chong et 
al. 2004; D’Orsagna et al. 2007; Jacobsen et al. 2008; De Milito et al. 2001). 
 
Early initiation of ART appears to reverse an important consequence of chronic HIV 
infection, namely the of IgM+ memory B-cells (Titanji et al. 2005; Moir and Fauci. 
2008). 
    
1.3 MONOCLONAL PROTEINS 
 
A paraprotein or monoclonal or M-peak refers to an immunoglobulin molecule produced 
by a clone of plasma or B-cells and is usually detected as a band in the alpha to gamma 
area on protein electrophoresis of serum or urine. 
 
Monoclonal immunoglobulins are found in a number of disorders, benign and malignant.  
Best known are the plasma cell dyscrasias, multiple myeloma (MM), amyloidosis, 
plasmacytomas and B-cell lymphoproliferative disorders such as Waldenströms 
macroglobulinaemia, small lymphocytic lymphoma and other B-cell lymphomas (Pontet. 
2005).  
 
Other disorders associated with monoclonal proteins include auto-immune disease 
(systemic lupus erythrematosus (SLE), Sjögren’s syndrome and diabetes), HIV and other 
serious infections (septicaemia, TB and meningitis), chronic liver disease (cirrhosis, 
hepatitis), malignant or benign tumors and other haematological neoplasms 
(myeloproliferative disorders, Hodgkin’s disease) (Pontet. 2005).  
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1.3.1 Premalignant plasma cell disorders: 
 
1.3.1.1 Monoclonal gammopathy of undetermined significance (MGUS) 
 
MGUS is a premalignant plasma cell proliferative disorder, the feature of which is the 
presence of monoclonal immunoglobulin or M protein in the serum. MGUS is found in 
3.2% of the general population 50 years and older and 5.3% of those older than 70 years 
(Kyle et al. 2006). Patients with MGUS have a serum M protein of less than 30g/L, bone 
marrow plasma cells of less than 10%, and no anaemia, hypercalcaemia, lytic bone 
lesions or renal failure that would be a sign of a malignant plasma disorder. MGUS is 
asymptomatic, but does progress to MM or related malignancy at a rate of 1% per year. 
Persons with MGUS must be followed-up annually. Risk factors were very difficult to 
identify for the progression of MGUS. The type and size of M protein were the only 
predictive risk factor of progression (IgM and IgA) (Kyle et al. 2006). In a study by 
Cesana et al it was found that a bone marrow plasma cell count of 6% to 9% had twice 
the risk of progression as compared with bone marrow plasma cell of less than 5% 
(Cesana et al. 2002). 
 
1.3.1.2 Smouldering MM (SMM) 
 
SMM was first reported in 1980 and is an asymptomatic premalignant plasma cell 
disorder with the potential risk of progression to symptomatic MM.  The definition for 
SMM is as follows: a serum M protein level greater than or equal to 30g/L and/or bone 
marrow plasma cells greater than or equal to 10%, no anaemia, hypercalcaemia, renal 
failure, or lytic bone lesions, no end organ damage or symptoms of myeloma (Dispenzieri 
et al. 2008). It is important that SMM be distinguished from the clinically aggressive MM 
and the more benign MGUS with much lower risk of progression (Kyle et al. 2002). In a 
study by Dispenzieri et al the risk of progression from SMM to MM was determined if 
the patients with SMM meet both the M protein and bone marrow criteria. After 10 years 
77% of the patients with plasma cells greater or equal to 10% and M protein greater than 
or equal to 30g/L, 64% of the patients with plasma cells greater or equal to 10% and M 
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protein less than 30 g/L and 33% of the patients with plasma cells less than 10% and M 
protein was greater or equal than 30g/L progress to MM (Dispenzieri et al. 2008). 
 
1.3.2 Malignant plasma cell disorders: 
 
1.3.2.1 Multiple myeloma (MM) 
 
MM is a haematological plasma cell proliferative malignancy characterized by the 
neoplastic proliferation of a single clone of plasma cells producing a monoclonal 
immunoglobulin. The clone proliferates in the bone marrow and produces osteolytic bone 
lesions, osteopaenia, osteoporosis and /or pathologic fractures. The monoclonal proteins 
may cause organ damage, often leading to renal insufficiency and /or renal failure. The 
mean age of diagnosis for multiple myeloma is 66 years with only 2% of patients 
younger than 40 years (Kyle et al. 2003).  
 
The diagnosis of MM is based on the presence of 10% or more plasma cells in the bone 
marrow, monoclonal immunoglobulins in the serum or urine and a monoclonal band of 
30g/L or more on serum protein electrophoresis with related organ or tissue impairment 
such as renal failure, hypercalcaemia, anaemia and symptoms of bone lesions (Kyle et al. 
2003, Smith et al. 2006).  
 
1.3.2.2 Light chain MM 
 
LCMM has the clinical features of MM. Bence Jones protein in urine protein 
electrophoresis is positive with the absence of intact monoclonal immunoglobulins in 
serum protein electrophoresis (Bridgen and Webber. 2000). 
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1.3.2.3 Nonsecretory MM (NSMM) 
 
NSMM has the same symptoms of MM, but the tumour plasma cells contain no 
detectable immunoglobulins. There are no monoclonal bands in serum and urine protein 
electrophoresis (Dreicer and Alexanian. 1982; Drayson et al. 2001).  
 
1.3.2.4 Intact Immunoglobulin MM 
 
Patients with intact immunoglobulin MM have a monoclonal band in serum protein 
electrophoresis and no bands in urine protein electrophoresis (Blade and Kyle. 1999). 
 
1.3.3 Waldenströms Macroglobulinaemia 
 
Waldenströms macroglobulinaemia is a low tumor burden lymphoproliferative disorder 
that is associated with the production of monoclonal IgM. It is 5-10% as frequent as 
myeloma and the mean age of presentation is 65 years with a mean survival of five years 
and 20% of the patients live more than 10 years. Patients have high concentrations of 
IgM with infiltration of the bone marrow, spleen, liver and lymph nodes. Serum IgM 
quantification is important for diagnosis and monitoring (Owen et al. 2003). 
 
1.3.4 Amyloidosis  
 
Amyloidosis is a protein conformation disorder.  The main feature is the accumulation of 
monoclonal free light chains or their fragments as amyloid deposits in organs.  Patients 
present with heart or renal failure, but the skin, peripheral nerves and other organs may 
also be involved.  The mean age of presentation is 70 years and it is very rare before 40 
years.   The mean survival is 12 months.  It is caused by a slow growing clone of plasma 
cells secreting monoclonal light chains, mainly the lambda (λ) type.  Monoclonal protein 
is an important diagnostic feature and is found in serum and urine of most patients.  
Protein electrophoresis indicates a typical nephrotic pattern, with low albumin, elevated 
α2 - and low γ – fractions with no observable monoclonal peak.  Immunofixation 
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electrophoresis shows polyclonal immunoglobulin in the γ - fraction and small 
monoclonal λ - protein in the ß/γ region.  Urine electrophoresis shows a considerable 
amount of protein, particularly albumin with a small monoclonal spike.  Immunofixation 
electrophoresis shows a monoclonal λ protein against a background of polyclonal kappa 
() and λ light chains.  The monoclonal band in both serum and urine is too small to 
quantify (Kyle and Gertz. 1995; Abrahams et al. 2003). 
 
1.4 INCIDENCE OF MONOCLONAL PROTEINS IN HIV 
 
Infection with HIV is associated with an increased frequency of monoclonal proteins on 
serum protein electrophoresis (Lefrere et al. 1993).  The prevalence of monoclonal 
protein was higher in the earlier studies (Heriot et al. 1985; Crapper et al. 1987; Tubat-
Herrera et al. 1993), with recent studies showing a much lower prevalence, probably due 
to ART( Jansen van Vuuren et al. 2010) 
 
In 1985 Heriot et al performed serum and urine protein electrophoresis on agarose gel on 
24 patients with clinical HIV infection, 9 of which had lymphadenopathy syndrome 
(LAS) and 15 with AIDS.  Of these, 8/15 with AIDS and 6/9 patients with LAS had 
paraproteins on serum protein electrophoresis. Twelve of the patients had IgG κ type 
paraprotein and two had IgG without light chains.  All the patients expressing a light 
chain had a κ paraprotein (Heriot et al. 1985). 
 
In 1987 Crapper et al studied 130 homosexual men for the presence of monoclonal bands 
on serum protein electrophoresis.  Sixty-five were HIV positive and 65 negative.  The 
mean age was 33 years (21-42 yrs). Monoclonal bands were found in 6 patients in the 
HIV positive group and in none of the HIV negative group.  Four were single paraprotein 
peaks and two were multiple oligoclonal bands.  The prevalence of monoclonal protein 
was 9% (Crapper et al. 1987).   
 
In 1987 Lefrere et al screened 243 HIV positive patients diagnosed as HIV positive on 
ELISA for monoclonal proteins.  Their mean age was 34 years.  Monoclonal proteins 
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were found in 6 patients (2.5%), all IgG κ and IgG λ.  No Bence Jones proteins were 
present.  The CD4+ counts were higher than 200 in the six patients.  The peaks of the 
monoclonal protein varied in size from 2-7 g/L (Lefrere et al. 1993).   
 
In 2007 Konstantinopoulos et al investigated 320 HIV-infected patients, of which   253 
were males and 67 were females with a mean age of 42 years (7 – 67 years).  There was 
no significant difference in the viral load and the CD4+ T-cell count between males and 
females.  Females had a higher average IgG, but the difference in IgM and IgA was not 
significant.  There were 139 with increased IgG, 72 with increased IgA and 35 with 
increased IgM levels.  In 11 samples, all three immunoglobulins were increased and in 1 
sample all three immunoglobulins were decreased.  Of the 14 (4.4%) monoclonal bands, 
13 were of the IgG κ type and 1 was IgG λ.  The average size of the monoclonal peak 
was 1.85 g/L (range 0.3 - 4.65 g/L).  Of the 26 (8.1%) samples with oligoclonal bands, 24 
patients had only IgG bands.  There were 13 samples with κ and λ bands present and 11 
samples had bands with a single light chain type.  Two oligoclonal samples had an IgA or 
IgM band together with an IgG band.  The 4 factors associated with banding according to 
their study were younger age, female sex, increased viral load and CD4+ T-cell count of  
≥ 350/μL. The study supports the hypothesis that elevated total IgG levels show 
oligoclonal or monoclonal bands as part of an immune response directed toward HIV and 
with increased HIV viral load the host B-cells respond by making more immunoglobulins 
directed at specific HIV epitopes, which can be detected as oligoclonal or monoclonal 
bands on serum protein electrophoresis.  The prevalence of bands in HIV-infected 
patients in this study were lower than previously reported, perhaps due to more effective 
ART available (Konstantinopoulos et al. 2007). 
 
In a recent local study by Jansen van Vuuren et al published in 2010, 368 HIV- infected 
patients were investigated. There were 127 males and 241 females enrolled with a mean 
age of 37.7(17-70) years. The males were older than the females with a mean age of 40 
years for males and 36.5 years for females. Monoclonal bands were found in 12 patients 
(3.2%). Oligoclonal bands were found in 14 patients (3.8%). Three hundred and twenty 
four patients were on ART for a mean duration of 19.6 months. The presence of bands 
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was associated with a shorter duration of ART. Viral load and CD4+ count did not differ 
significantly from patients without monoclonal bands. Most monoclonal bands were of 
low concentration and of the IgG isotype. IgG was the only heavy chain isotype 
identified and was present in 10/12 (83%) monoclonal bands and 9/14 (64%) of the 
oligoclonal bands. Kappa was the light chain most often found in monoclonal bands, 
9/12(75%). Oligoclonal bands had 7/14 (50%)  light chains only and the other 7/14 
(50%) had both  and  light chains. One patient had only an IgG heavy chain without a 
light chain. The study confirms that the prevalence of monoclonal and oligoclonal bands 
are higher in the HIV positive patients on ART compared to the general population 
(Jansen van Vuuren et al. 2010). 
 
Another South African study was published in 2011, where a group from Kwazulu-Natal 
performed a retrospective, anonymous analysis of routine laboratory results to describe 
the effect of HIV status on serum protein electrophoresis patterns. They examined 331 
serum protein electrophoresis patterns of routine tests sent to the laboratory. One hundred 
and two of these were HIV seropositive and 229 HIV seronegative. Those without HIV 
status results were excluded from the study. They found that monoclonal bands were not 
increased in HIV-positive patients, but these patients were younger and had a higher 
incidence of polyclonal and oligoclonal bands and total proteins when compared to HIV-
negative patients (Tathiah et al. 2011). 
  
1.5 SIGNIFICANCE OF MONOCLONAL BANDS IN HIV PATIENTS   
 
The significance of these bands in HIV-infected subjects has been investigated in 
numerous studies. 
 
In 1989 Ng et al studied seven HIV–infected subjects with paraproteins in their serum 
and performed immunoglobulin subclass typing.  They found that five had IgG1 κ, one 
had IgG3 λ and one had IgA λ.  They found that IgG1 paraproteins in the sera of HIV-1 
infected subjects reflect a vigorous and normal polyclonal immune response to HIV-1 
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viral antigens and the clinical significance of the IgG3 λ and IgA λ paraprotein was 
unclear (Ng et al. 1989). 
 
In 1992 Turbat-Herrera et al investigated 27 bone marrow aspirates and biopsies of HIV 
positive subjects with plasmacytosis for the amount of plasma cells.  Serum protein 
electrophoresis and immunoelectrophoresis was performed on 18 of the patients.  Five 
had monoclonal proteins, 11 had polyclonal hypergammaglobulinaemia and 2 had a 
normal serum protein electrophoresis pattern.  The 5 patients with monoclonal 
paraproteins were identified as two with IgA κ, one with IgG λ and two with IgG κ.  
There were 5-30% plasma cells in the bone marrow with 1-20% atypical plasma cells.  
All the subjects were polyclonal on immuno-histochemical staining.  There was no 
correlation between bone marrow plasmacytosis and monoclonal proteins on protein 
electrophoresis (Turbat-Herrera et al. 1993).  
 
Amara et al performed a retrospective analysis on 25 HIV positive patients (24 males and 
1 female) with detectable serum monoclonal protein in 2006.  The mean age was 44 years 
(21-69 years).  Various clinical presentations led to the finding of monoclonal proteins 
with serum protein electrophoresis.  Serum monoclonal proteins varied between 2-60g/L 
with a mean monoclonal concentration of 30g/L.  Of the 25 monoclonal proteins, 24 were 
of the IgG type and 1 IgA. Urine protein immunoelectrophoresis was performed on 20 of 
the 25 patients with Bence Jones. Serum immunoglobulin was performed on 23 patients.  
Seven had normal immunoglobulin, 14 had IgG hypergammaglobulinaemia and 2 had 
hypogammaglobulinaemia.  There was no correlation with the CD4+ count.  After a 
follow-up duration of 21 months, 9 of the 16 monoclonal peaks decreased, 7 did not 
decrease and none disappeared while on HAART.  Seven (28%) of the 25 patients 
developed a malignancy.  One patient developed MM, 1 marginal zone lymphoma, 2 
Kaposi sarcoma, 2 plasmacytoma and 1 testicular cancer, suggesting an increased risk for 
malignancy in these patients (Amara et al. 2006). 
 
In 1992 Lefrere et al performed a study on 341 symptomless HIV positive subjects 
diagnosed on ELISA over a 6 year period to detect serum monoclonal proteins.  Eleven 
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of the 341 subjects had monoclonal proteins.  Of the 11 subjects, 7 monoclonal peaks 
disappeared with follow-up, 2 individuals developed a second peak and 1 individual a 
third peak.  They concluded that monoclonal proteins in symptomless HIV-infected 
subjects does not signify a prelymphomatous state and may not be used as a predictive 
marker of disease progression (Lefrere et al. 1993).   
 
Pontet et al studied the immunoglobulins of 212 HIV-positive patients and followed them 
up for 13 years (1984-1997).   The qualitative features of the immunoglobulin can be 
divided into 3 groups, monoclonal Ig, minor abnormalities and polyclonal 
immunoglobulin.  The incidence of monoclonal immunoglobulin was 11.3%. The 
(male/female) sex ratio was 2.2 with 12.1% and 11.0% of monoclonal Ig in the female to 
male respectively.  The male/female ratio for monoclonal Ig is 0.91.  There was no 
increase in monoclonal immunoglobulin with age in female or in males.  Minor 
abnormalities were more in females (29%) than in males (18%).  This study showed that 
prevalence of monoclonal immunoglobulin is higher in HIV-positive than in the general 
population of the same age.  The survival curve shows that the presence of 
immunoglobulin abnormalities, monoclonal or minor, in HIV-positive patients has no 
prognostic significance (Pontet et al. 1998). 
 
1.6 FREE LIGHT CHAINS 
 
In 1962 Edelman and Gally showed that free light chains (FLC) prepared from IgG 
monoclonal proteins were the same as Bence Jones protein (Edelman and Gally. 1962). 
Antibody molecules have a two-fold symmetry and are composed of two identical heavy 
chains and two identical light chains, each containing variable and constant domains.  
The variable domains of each light chain, heavy chain pair combines to form an antigen-
binding site so that both chains contribute to the antigen-binding specificity of the 
antibody molecule as shown in figure 1.2.  Light chains are of two types, kappa () and 
lambda (λ) and any given antibody molecule has either  or λ chains, but never both. 
There are twice as many  as λ molecules produced in humans (Edelman and Gally. 
1962). 
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Figure 1.2 The antibody molecule showing the heavy and light chain structure  
 
Normal and abnormal plasma cells produce more light chains than heavy chains and the 
excess light chains are released into the bloodstream.  The FLC’s are cleared and 
metabolized by the kidneys.  Increases in serum FLC levels may occur due to decreased 
renal clearance. In patients with impaired renal clearance, the serum light chain levels 
may be elevated, but the free light chain κ:λ ratio will be normal.  Patients with an 
expansion of either κ or λ producing plasma cell clone, have an abnormal serum FLC κ:λ 
ratio.  This ratio is a very sensitive diagnostic test for plasma cell clones that have lost the 
ability to produce heavy chains and secrete only light chains.  Kappa monomeric FLC’s 
are smaller in size (25 kDa) than the λ dimeric FLC’s (50 kDa); therefore the κ 
monomeric molecules filter approximately three times faster (Solomon. 1985; Waldman 
et al. 1972; Miettinen and Kekki. 1967; Arfors et al. 1979). 
 
Immunoassays based on polyclonal antibodies were developed that could measure FLC’s 
at normal serum concentrations (Bradwell et al 2001). Their utility was made apparent 
when monoclonal FLC’s were detected in serum of patients classified as having 
“nonsecretory” myeloma (Drayson et al. 2001). FLC determination is important in the 
diagnosis of monoclonal light chain diseases such as primary amyloid and disorders that 
often do not have serum monoclonal proteins in high enough concentration to be detected 
and quantitated by protein electrophoresis (Katzmann et al. 2005).  
 
The serum FLC analysis provides a risk assessment for the progression of MGUS to MM. 
In a study where baseline serum samples were obtained with 30 days of diagnosis of 
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MGUS in 1148 patients, 737 (64%) had elevated levels of  and  FLCs.  An abnormal 
FLC ratio was detected in 379 (33%) patients. The risk of progression to MM or related 
malignancy at 10 years was 17% with an abnormal ratio compared with 5% with a 
normal ratio (Rajkumar et al. 2005). If MGUS is diagnosed, the FLC ratio can be used to 
segregate patients into high and low risk groups.  Patients with an abnormal FLC ratio 
have a 2.5 fold increased risk of progression (Rajkumar et al. 2005; Kyle et al. 2006).   
The serum FLC assay can be used to monitor the disease course in patients with a 
monoclonal protein that cannot be measured by protein electrophoresis.  By using the 
assay to monitor MM patients who present with unmeasurable levels of monoclonal 
protein in serum or urine protein electrophoresis, physicians can minimize the use of 
serial bone marrow biopsies and reduce the use of invasive techniques. Furthermore, by 
measuring the serum FLC in a patient’s serum, the need for collecting a 24-hour urine 
sample is eliminated. This is advantageous, as urine collection is inconvenient for 
patients and the laboratory workload is reduced by eliminating the need to process urine 
samples (Rajkumar et al. 2005). 
 
In a study of 273 patients with smouldering MM, the light chain type was κ in 68% and λ 
in 32%.  An abnormal FLC ratio was detected in 245 patients (90%).  An increasingly 
abnormal FLC ratio was associated with a higher risk for progression to active MM.  
Patients with a normal or near normal ratio had a rate of progression of 5% a year, while 
patients with increasingly abnormal ratio had a progressive increase in the risk of 
progression of about 8.1% per year (Rajkumar et al. 2004). 
 
In a study of 116 patients who met the criteria for solitary bone plasmacytoma, 53% had 
a normal FLC ratio and 47% had an abnormal ratio.  Patients with an abnormal ratio had 
a higher incidence of monoclonal protein in the urine and a larger serum monoclonal 
spike (Dispenzieri et al. 2008). 
 
Bradwell et el and Nowrousian et al showed that patients with LCMM have abnormal 
concentrations of serum FLC and abnormal κ/λ ratios and that immunoassays for serum 
FLC are more sensitive for identifying of Bence Jones protein than immunofixation of 
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urine (Bradwell et al. 2003; Dingle et al. 2006).  Drayson et al showed that patients with 
nonsecretory MM have elevated κ or λ FLC concentration and abnormal κ/λ ratios 
(Drayson et al. 2001). In study by Mead et al it was found that patients had elevated, 
normal or reduced concentration of FLC but the κ/λ ratios were all abnormal 
(Nowrousian et al. 2003). 
 
Patients with Waldenströms macroglobulinaemia have abnormal FLC concentrations and/ 
or κ/λ ratios (Mead et al. 2004). Various studies showed that serum FLC measurement is 
a useful screening test and supplement other tests and the quantitative nature of FLC 
immunoassays have a value in monitoring patients (Bradwell et al. 2002; Lachmann et al. 
2003; Katzmann et al. 2002; Abrahams et al. 2003).  
 
1.6.1 Reference intervals 
Reference intervals for FLC’s were established at the Mayo Clinic using 282 mainly 
Caucasian elderly subjects (Katzmann et al. 2002).  No local reference intervals have 
been established in South Africa yet, although it has been advised to establish local 
reference intervals (Pattenden et al. 2007). 
 
Racial differences have been described in the prevalence of MGUS and MM (Weiss et al. 
2011; Landgren and Weiss. 2009) and in immunoglobulin levels in HIV subjects 
(McGowan et al. 2006).  As most of our cohort was younger subjects with HIV of either 
black or mixed ancestry ethnicity, the need to verify the manufacturer’s reference 
intervals was identified. 
 
1.6.2 FLC Assay: 
 
Laboratory investigations for possible B-cell disorders currently require both urine and 
serum samples (Akar et al. 2005). B-cell disorders cannot be excluded without analysis of 
urine samples by existing methods, because LCMM and NSMM account for 15% - 20% 
of new diagnoses.  In many of these cases the serum FLC concentrations are below the 
detection limits of conventional immunofixation methods (Akar et al. 2005). It is often 
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difficult to collect serum and urine samples and concurrent urine samples are received 
from less than 40% of patients (Akar et al. 2005). 
 
The serum FLC automated assay was developed in the early 2000s to detect light-chain 
epitopes that are exposed only when not bound to a heavy chain. The assay quantifies  
and  FLC’s and is now routinely used in the diagnosis and management of several 
plasma cell proliferative disorders, including MGUS, light-chain amyloidosis and MM 
(Hill et al. 2006). 
 
Studies have shown that serum FLC assays are more sensitive than serum protein 
electrophoresis and urine protein electrophoresis for the detection of urine light chains in 
MM, NSMM and primary amyloidosis.  Serum FLC cannot replace serum protein 
electrophoresis in a screening protocol for monoclonal gammopathies, because they are 
slightly less sensitive when screening for intact immunoglobulin MM. However, they 
have the potential to replace urine protein electrophoresis, as they have a lower limit of 
detection for FLC and a high percentage of serum samples are sent without concurrent 
urine samples. Serum FLC in addition to serum protein electrophoresis may improve the 
detection of monoclonal gammopathies (Akar et al. 2005). 
 
A recent study examining only serum samples showed that additional patients with B-cell 
disorders were identified when serum FLC measurement was used in conjunction with 
capillary zone electrophoresis (Bakshi et al. 2005). 
 
However, the FLC assay is not without its limitations. Variation in assay reagents in 
different lot numbers can be a problem. Both polyclonal and monoclonal serum FLC’s 
have been found to dilute in a nonlinear fashion, leading to underestimation in the 
absence of off-line dilution (Bakshi et al. 2005). False high results may occur due to 
polymerization of light chains (Tate et al 2007; Abrahams et al. 2002).  In a study by Hill 
et al false positive results were detected (Hill et al. 2006).  Increased immunoglobulins, 
renal impairment and/or acute phase responses lead to more false positive results (Akar et 
al. 2005). False low serum FLC results may be obtained due to antigen excess when very 
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high concentrations are present (Édmond et al. 2007). Nephelometric assays measure 
light scatter caused by the formation of immune complexes in solution and are subject to 
limitations inherent in antigen-antibody reactions. Newly identified cases with 
abnormally high serum FLC ratios should be retested with a higher dilution, because of 
the potential for FLC antigen excess (Hill et al. 2006). It has been proposed that serum 
protein electrophoresis and serum FLC’s be used as first line tests for the investigation of 
possible B-cell disorders, because no substantial pathology would have been missed by 
replacing urine Bence Jones Protein with serum FLC’s (Akar et al. 2005). However, the 
assay has also been criticized for its high level of imprecision, the variations on various 
platforms and the fact that assays and standards are only provided by one company 
(Sheldon 2007). 
 
 
Method validation is a standard process in every good laboratory in judging the 
acceptability of a new method (Percy-Robb et al. 1980).  The decision on acceptability 
depends on defining quality standards that provide objective statements on how good a 
test should be.  These quality standards “criteria for acceptable performance” can be 
retrieved from sources such as CLIA or be based on biological variation data.   
 
Dr Westgard refers to method validation simply as “error assessment”.  The focus is on 
analytical errors and how these errors impact in the interpretation of a test.  While a 
comparison of method experiment can reveal the different type of errors, there are 
specifically designed experiments for each one of them (Westgard 2008). The different 
type of errors observed and the experiments required in identifying them are shown in 
table 1.1. 
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Table 1.1 Method validation studies and the errors they detect 
 
Type of 
Analytical 
Error 
Evaluation Experiment 
Preliminary Final 
Random Error Replication  
Constant Error Interference Comparison 
of 
Methods 
Proportional Error Recovery 
 Linearity experiment  
 
 
1.7 PRESENT KNOWLEDGE OF FLC CONCENTRATION IN HIV 
 
A Pubmed search showed that there is currently only one study examining FLC in HIV 
infection. Landgren et al found that FLC were elevated in HIV-infected subjects 
compared to the general population, and strongly predicted NHL risk, independent of 
CD4+ count.  In contrast, markers of monoclonal B-cell proliferation (abnormal FLC 
ratio) were not associated with NHL development.  FLC’s may be a sensitive marker of 
polyclonal B-cell activation or dysfunction and could identify HIV-infected person at 
increased NHL risk (Landgren et al. 2010). De Filippi et al reported on 2 HIV-negative 
subjects presenting with primary effusion lymphoma (PEL). These patients present with 
HIV-like symptoms (De Filippi et al. 2009). 
 
A recent publication in Clinical Chemistry (Hutchison and Landgren. 2011) discussed the 
use of FLC measurement as a marker of immune stimulation and inflammation. They 
discussed its potential use as a biomarker of activation of the B-cell lineage and 
mentioned the study by Landgren et al (Landgren et al. 2010). 
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1.8 HYPOTHESIS 
 
FLC is a marker of B cell dysfunction, and as HIV is associated with B cell dysfunction, 
we hypothesized that FLC levels and FLC ratio will be abnormal in HIV-infected 
individuals. 
 
1.9 AIMS OF STUDY 
 
1) To validate the FLC Assay using the Beckman Immage® 
2) To develop local FLC reference intervals 
3) To determine FLC levels and κ/λ ratios in HIV positive subjects (mainly on 
HAART) 
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SECTION II: MATERIALS AND METHODS 
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2.1 METHOD VALIDATION: 
 
As described in the literature review, method validation is performed on all new tests 
prior to their routine introduction in the laboratory as a means of evaluating errors. 
 
2.1.1 Linearity study 
 
The linearity study was performed in 2 parts, namely on linearity fluid and on pooled 
serum samples obtained from routine samples sent to the Chemical Pathology laboratory. 
The linear range specified by the manufacturer is 6.0-180mg/L for  FLC and 4.8-162 
mg/L for . 
 
2.1.1.1 Using Linearity Fluid 
 
The  fluid was diluted to a value of 64.47 mg/l, which is in the linear range, using 
dilutions made according to the FreeliteTM instructions. These were then analysed on the 
Beckman IMMAGE® in triplicate to negate the effect of random errors (imprecision) and 
the results were then compared to the assigned values of the linearity fluid.  
 
The  fluid was diluted to a value of 135.67 mg/l, which is in the linear range, using 
dilutions made according to the FreeliteTM instructions. These were then analysed on the 
Beckman IMMAGE® in triplicate to negate the effect of random errors (imprecision) and 
the results were then compared to the assigned values of the linearity fluid. 
 
2.1.1.2 Using Pooled Serum 
 
Serum obtained from routine samples sent to the Chemical Pathology laboratory was 
pooled and a  value of 38.92 mg/l was obtained, which is in the linear range. Dilutions 
were made according to the FreeliteTM instructions using the manufacturer’s diluent. 
These were then analysed on the Beckman IMMAGE® in triplicate to negate the effect of 
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random errors (imprecision) and the results were then compared to the determined values 
of the pool sample. 
 
Serum obtained from routine samples sent to the Chemical Pathology laboratory was 
pooled and a  value of 49.47 mg/l was obtained, which is in the linear range. Dilutions 
were made according to the FreeliteTM instructions using the manufacturer’s diluent. 
These were then analysed on the Beckman IMMAGE® in triplicate to negate the effect of 
random errors (imprecision) and the results were then compared to the determined values 
of the pool sample. 
 
2.1.2 Recovery experiment 
 
2.1.2.1 Kappa Recovery: 
 
Six patient samples with different concentrations of  FLC were obtained and spiked 
with a high  control (31.9 mg/l). This control was spiked into an aliquot of the patient 
samples in a 1:10 dilution. This sample was then analyzed in duplicate to negate the 
effect of random errors and the recovery was then calculated for each individual sample. 
 
2.1.2.2 Lambda Recovery: 
 
Five patient samples with different concentrations of  FLC were obtained and spiked 
with a high  control (46.2 mg/l). This control was spiked into an aliquot of the patient 
samples in a 1:10 dilution. This sample was then analyzed in duplicate to negate the 
effect of random errors and the recovery was then calculated for each individual sample. 
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2.1.3 Interference Studies 
 
2.1.3.1 Haemolysis interference study 
 
A haemolysate was prepared using the modified osmotic shock method in the laboratory 
and samples with different haemoglobin (Hb) concentrations were made using the above 
haemolysate. The final Hb concentrations were as follows:  12.1 g/dl, 4.15 g/dl, 3.25 g/dl, 
2.5 g/dl and 2.1g/dl. Four serum pools were made, namely high  (50.8 mg/l), high  
(48.8 mg/l), low  (10.85 mg/l) and low  (19.15 mg/l). The interferent (Hb) was then 
spiked into the above pools in a dilution of 1:10. These samples were analyzed in 
duplicate to negate the effects of random errors. A ± 10% allowable error from baseline 
was used to determine acceptability for the different Hb concentrations as advised by the 
manufacturer. 
 
 2.1.3.2 Bilirubin interference study 
 
A sample with a bilirubin of 371.2 mol/l was used in the interference study. Samples 
with different bilirubin concentrations were made by diluting the above sample. The final 
bilirubin concentrations were as follows: 371.2 mol/l (neat), 117.4 mol/l, 86.7 mol/l, 
71.3 mol/l and 41.7 mol/l. Four serum pools were made, namely high  (33.45 mg/l), 
high  (39.65 mg/l), low  (16.7 mg/l) and low  (18.1 mg/l). The interferent (bilirubin) 
was spiked into the above pools in a dilution of 1:10. These samples were then analyzed 
in duplicate to negate the effects of random errors. A ± 10% and ± 20% allowable error 
from baseline was used to determine the acceptability for the different bilirubin 
concentrations as advised by the manufacturer. 
 
2.1.3.3 Rheumatoid factor interference study 
 
A sample with a rheumatoid factor (RF) value of 1850 IU/ml was retrieved from the 
department of Immunology for the interference study. The sample was diluted using the 
Beckman diluent, creating concentrations of 581, 486, 385 and 311 IU/ml. Four serum 
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pools were made, namely high  (45.00 mg/l), high  (50.65 mg/l), low  (10.17 mg/l) 
and low  (20.8 mg/l). The interferent (RF) was spiked into the above pool in a dilution 
of 1:10. These samples were then analyzed in duplicate to negate the effects of random 
errors. A ± 10% and ± 20% allowable error from baseline was used to determine the 
acceptability for the different RF concentrations as advised by the manufacturer. 
 
2.1.3.4 Triglyceride interference study 
 
A lipaemic sample with a triglyceride value of 25.82 mmol/l was used for the 
interference study. Samples with different triglyceride concentrations were made by 
diluting the above sample. The final triglyceride concentrations were as follows: 25.82 
mmol/l (neat), 9.31 mmol/l, 7.74 mmol/l, 5.79 mmol/l and 5.06 mmol/l. Four serum pools 
were made, namely high  (45.00 mg/l), high  (50.65 mg/l), low  (10.17 mg/l) and low 
 (20.8 mg/l). The interferent (triglyceride) was spiked into the above pools in a dilution 
of 1:10. These samples were then analyzed in duplicate to negate the effects of random 
errors. A ± 10% and ± 20% allowable error from baseline was used to determine the 
acceptability for the different triglyceride concentrations as advised by the manufacturer. 
 
2.1.4 Imprecision Evaluation 
 
We utilized the CLSI EP15 protocol to verify the performance for precision and trueness 
of the test (Chesher 2008). 
 
Precision was tested using pooled serum samples (high and low pool) for both  and  
light chains. Trueness was verified by using control material (high and low controls) for 
both  and . 
 
2.1.5 Method Comparison Study 
 
A comparison of methods experiment is performed to estimate the bias i.e. the inaccuracy 
or systematic error of a method.  This is carried out by analyzing patient samples on the 
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new method and on the comparative method. Forty samples were used to compare  FLC 
and 38 to compare  FLC. These samples were collected over a time period of one 
month. As they could not be analysed within two hours of each other, the samples were 
stored at -70C. The systematic errors are based on the differences observed between the 
methods.  It is therefore important that the statistics calculated provide information about 
the systematic error at medically important decision levels.  The important statistics 
include the correlation coefficient, regression equation and the difference plot.  
 
Since the FLC test has not been introduced on the regular test menu of our laboratory, we 
compared our method (nephelometric on the Beckman Immage®) to a same established 
method used at another laboratory. 
 
2.1.5.1 Correlation 
 
Correlation describes the level of agreement between two methods and is a very 
important statistical tool that confers reliability of the regression statistics calculated. 
 
2.1.5.2 Regression statistics 
 
The relevant errors in a method evaluation include the random, proportional and constant 
errors.  The regression statistics is an important statistical tool that allows one to estimate 
the above errors.  The systematic error can also very importantly be estimated at any 
concentration using the regression equation.  This is important in assessing the systematic 
error at key medical decision limits.   
 
In view of the limitations observed with simple linear regression statistics, Deming’s 
Regression Statistics was used in the analysis.  
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2.1.5.3 Difference plot (Bland-Altman) 
 
The difference or Bland-Altman plot allows for a graphical display of the bias observed 
in relation to the comparative method.  It is constructed as follows:  The mean of xi and yi 
is determined for every sample pair .Yi is then subtracted from the calculated mean and 
expressed graphically.  This plot allows for a more objective appreciation of the bias at 
key decision limits. 
 
2.2 ESTABLISHING LOCAL SERUM REFERENCE INTERVALS: 
 
Blood was obtained from 120 normal subjects, namely 78 healthy HIV negative blood 
donors and 42 healthy black volunteers who were participating as controls in another 
study being performed by the Division of Haematology. The following blood tests were 
performed on each subject: total protein, IgG, IgA, IgM, creatinine, protein 
electrophoresis,  FLC and  FLC. Using the results of  and  FLC, a FLC ratio was 
determined. Informed consent was obtained from all subjects prior to enrolment (see 
Appendix 1) and participation was voluntary. 
 
2.3 FLC IN HIV PATIENTS  
 
This was a retrospective descriptive study, using blood samples stored at -70C from a 
previous study obtained from patients with HIV infection attending clinics at Karl 
Bremer and TC Newman Hospitals in the Western Cape. Stability studies on FLC’s are 
still ongoing, but after discussion with the scientific advisor of the Binding Site, it was 
decided that the samples would be stable at this temperature for this time period. 
 
2.3.1 Inclusion Criteria 
 
Any patient, known with HIV infection, whether receiving ART or not, followed up at 
Karl Bremer or TC Newman Infectious Diseases Clinic was eligible for enrolment in the 
study.  Patients were enrolled consecutively as they presented for follow-up at the clinic. 
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2.3.2 Exclusion Criteria 
 
Children were excluded from this study. 
 
2.3.3 Clinical Data 
 
Clinical information was recorded by means of a form filled in by the investigator from 
information in the medical record and by means of patient interview. The data collected 
included: 
 Demographic details: age, gender and ethnic group.  
 Stage of disease: WHO stage of disease, most recent CD4+ count and viral load.  
 Medical history: previous and current serious illness e.g. tuberculosis, 
malignancy, auto-immune disease or viral hepatitis.  
 ART: duration of treatment. 
 
2.3.4 Ethical Consideration 
 
The study was carried out in accordance with the Declaration of Helsinki and ICH GCP 
guidelines. The study protocol was approved by the University of Stellenbosch Ethics 
Committee (see Appendix 2). All patients signed an informed consent form (see 
Appendix 3).  Patient confidentiality was maintained at all times. The data capture sheets 
containing clinical and demographic information reflected a study number only, and 
specimens and results were labeled with the study number only. Identifying information 
was kept separately to protect confidentiality. 
 
2.3.5 Determination of FLC 
 
Kappa and  FLC were determined on the Beckmann Coulter IMMAGE® by 
nephelometry.  It involves the addition of the serum sample to a solution containing the 
appropriate antibody in a cuvette.  A beam of light is passed through the cuvette and as 
the antigen-antibody reaction proceeds, the light passing through the cuvette is scattered 
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increasingly as insoluble immune complexes are formed.  The scattered light is 
monitored by measuring the decrease in intensity of the beam of light.  The antibody in 
the cuvette is in excess, thus the amount of immune complex formed is proportional to 
the antigen concentration.   
 
2.3.6 Determination of Total Protein 
 
Total protein used for quantifying the various protein fractions by densitometry, was 
determined on the ADVIA™ 1800 (Siemens) clinical chemistry analyzer. The method is 
based on the method of Weichselbaum, utilizing the biuret reagent and measuring the 
endpoint reaction at 545nm. Total protein is reported in gram per litre (g/L).  
 
2.3.7 Determination of Immunoglobulins 
 
IgG, IgA and IgM were determined by polyethylene glycol-enhanced 
immunoturbidimetric method on the ADVIA™ 1800 (Siemens).  Polyethylene glycol 
accelerates the antigen-antibody interaction as described in the work of Hellsing.  
 
2.3.8 Determination of Creatinine  
 
Creatinine was determined on the Beckman Coulter CX7® by means of the Jaffe rate 
method. Creatinine is reported in mol/l. 
 
2.3.9 Determination of albumin and gamma globulins  
 
Albumin and gamma globulins were determined densitometrically from the 
electrophoresis using agarose gel electrophoresis.  
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2.3.10 Data Processing 
 
Data was analyzed with the help of a statistician, using STATISTICA version 10 
(StatSoft Inc.) and Microsoft® Excel®. The calculations were performed in STATISTICA 
and Microsoft® Excel® was used to graphically display the results of the calculations. 
 
Descriptive statistics were used to analyze each parameter in terms of distribution, mean, 
median, quartiles, maximum and minimum values and standard deviation.  
 
Continuous variables were compared against each other using regression and correlation 
analysis. For data with a normal distribution, Pearson’s correlation coefficient was 
performed. The Spearman rank correlation coefficient was used for data with a non-
normal distribution (Pipkin).  
 
The Analysis of Variance (ANOVA) was used for non-continuous variables to compare 
two or more groups if the data are normally distributed.  
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SECTION III: RESULTS  
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3.1 METHOD VALIDATION 
 
3.1.1 Linearity study 
 
3.1.1.1 Using Linearity Fluid 
 
The results were linear within the recommended range for both  and  FLC’s using 
linearity fluid, as shown in figures 3.1 and 3.2. 
 
 
Figure 3.1 Results of the linearity study for  FLC using linearity fluid provided by the 
manufacturer 
 
 
 
Figure 3.2 Results of the linearity study for  FLC using linearity fluid provided by the 
manufacturer 
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3.1.1.2 Using Pooled Serum 
 
The results were linear within the recommended range for both  and  FLC’s using 
pooled serum samples as shown in figures 3.3 and 3.4. 
 
 
 
Figure 3.3 Results of the linearity study for  FLC using pooled serum 
 
 
 
 
Figure 3.4 Results of the linearity study for  FLC using pooled serum 
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3.1.2 Recovery experiment 
 
3.1.2.1 Kappa Recovery: 
 
  Control (high) 31.9 mg/l   
      
 Base Spiked      Difference Added
% 
Recovery 
Sample 1 10.90 13.00 2.10 3.19 65.80 
Sample 2 4.60 7.23 2.63 3.19 82.45 
Sample 3 13.90 14.35 0.45 3.19 14.00 
Sample 4 23.75 24.10 0.35 3.19 10.97 
Sample 5 19.35 20.40 1.05 3.19 32.91 
Sample 6 12.20 13.35 1.15 3.19 36.05 
AVERAGE     40.36 
 
The average recovery was calculated to be 40.36%, indicating a large proportional error. 
This result could be due to matrix effect of individual samples as demonstrated above. 
After discussion with the manufacturer, it was decided to not repeat this study. 
Samples 1 and 2 showed a reasonable recovery, but the rest not. 
 
3.1.2.2 Lambda Recovery 
 
  Control (high) 46.2 mg/l  
      
 Base Spiked   Difference Added
% 
Recovery 
Sample 1 20.15 24.50 4.35 4.62 93.50 
Sample 2 42.35 46.80 4.45 4.62 96.32 
Sample 3 7.30 11.10 3.80 4.62 82.25 
Sample 4 2.47 7.10 4.63 4.62 100.20 
Sample 5 10.55 14.50 3.95 4.62 85.50 
AVERAGE     91.55 
 
The average recovery was calculated to be 91.55%, indicating a proportional error of 
8.45% 
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3.1.3 Interference studies 
 
3.1.3.1 Haemolysis interference study 
 
For  FLC, the low pool was within the 10% allowable error as shown in figure 3.5. 
However, the high pool was outside the allowable 10% error at a Hb concentration of 
3.23 g/dl as shown in figure 3.6. This could have been due to random error. 
 
 
 
Figure 3.5 Hb interference at low  FLC levels 
 
 
 
 
Figure 3.6 Hb interference at high  FLC levels 
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As can be seen in figures 3.7 and 3.8, both the low and high pools of , the results 
obtained were within the 10% allowable error indicating minimal Hb interference. 
 
 
 
Figure 3.7 Hb interference at low  FLC levels 
 
 
 
Figure 3.8 Hb interference at high  FLC levels 
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3.1.3.2 Bilirubin interference study 
 
Bilirubin did not lead to interference in excess of the allowable 20% deviation with either 
high or low  levels, as is shown in figures 3.9 and 3.10. 
 
 
Figure 3.9 Bilirubin interference at low  FLC levels 
 
 
 
Figure 3.10 Bilirubin interference at high  FLC levels 
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Bilirubin did not lead to interference in excess of the allowable 20% deviation with either 
high or low  levels, as is shown in figures 3.11 and 3.12. 
 
 
 
Figure 3.11 Bilirubin interference at low  FLC levels 
 
 
 
 
Figure 3.12 Bilirubin interference at high  FLC levels 
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3.1.3.3 Rheumatoid factor interference study 
 
RF did not lead to interference in excess of the allowable 20% deviation with either high 
or low  levels, as is shown in figures 3.13 and 3.14. 
 
 
Figure 3.13 RF interference at low  FLC levels 
 
 
 
 
Figure 3.14 RF interference at high  FLC levels 
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RF did not lead to interference in excess of the allowable 20% deviation with either high 
or low  levels, as is shown in figures 3.15 and 3.16. 
 
 
Figure 3.15 RF interference at low  FLC levels 
 
 
 
 
Figure 3.16 RF interference at high  FLC levels 
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3.1.3.4 Triglyceride interference study 
 
For  FLC, no values exceeded the 20% deviation and it was concluded that triglyceride 
does not interfere with FLC analysis on the Beckman IMMAGE® as shown in figures 
3.17 and 3.18. 
 
 
 
 
Figure 3.17 Triglyceride interference at low  FLC levels 
 
 
 
Figure 3.18 Triglyceride interference at high  FLC levels 
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Similarly, for  FLC, no values exceeded the 20% deviation and it was concluded that 
triglyceride does not interfere with FLC analysis on the Beckman IMMAGE®  as shown 
in figures 3.19 and 3.20. 
 
 
Figure 3.19 Triglyceride interference at low  FLC levels 
 
 
 
 
Figure 3.20 Triglyceride interference at high  FLC levels 
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3.1.4 Imprecision evaluation 
 
3.1.4.1 Kappa FLC 
 
Using high  control, trueness was demonstrated, as the assigned value of 32.1 mg/l is 
included in the 95% confidence interval of 30.36 -33.52mg/l. 
 
Using low  control, Trueness was demonstrated, as the assigned value of 16.00 mg/l is 
included in the 95% confidence interval of 15.87 - 17.25mg/l. 
 
The EP15 protocol was used in determining the imprecision of  FLC (5-day protocol) on 
a high and low serum pool as shown in Table 3.1 and 3.2  
 
Table 3.1 Results of the imprecision studies for high  serum pool 
 
High  Serum Pool (Mean = 33.40g/l) SD (mg/l) CV (%) 
Within-run /Repeatability 2.167 6.49 
Within-Lab 2.415 7.23 
 
 
Table 3.2 Results of the imprecision studies for low  serum pool 
 
Low  Serum Pool (Mean = 10.84g/l) SD (mg/l) CV (%) 
Within-run /Repeatability 0.767 7.08 
Within-Lab 0.748 6.9 
 
The precision of the  FLC assay was acceptable. CV’s of <10% observed for all serum 
pools and trueness of the control material assigned values verified. 
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3.1.4.2 Lambda FLC 
 
Using high  control, trueness was demonstrated, as the assigned value of 56.6 mg/l is 
included in the 95% confidence interval of 50.84 – 57.52 mg/l. 
 
Using low  control, trueness could not be demonstrated as the assigned value of 28.3 
mg/l is not included in the 95% confidence interval of 24.22 -27.56mg/l, but when 
combined with the experimental uncertainty, trueness was demonstrated by the 
verification limits of 19.28 - 32.50 mg/l.      
 
The EP15 protocol was used in determining the imprecision of  FLC (5-day protocol) on 
a high and low serum pool as shown in Tables 3.3 and 3.4.  
 
Table 3.3 Results of the imprecision studies for high  serum pool 
 
 High  Serum Pool (Mean = 49.30g/l) SD (mg/l) CV (%) 
Within-run /Repeatability 1.907 3.87 
Within-Lab 2.088 4.24 
 
Table 3.4 Results of the imprecision studies for low  serum pool 
 
 
Low  Serum Pool (Mean = 19.44g/l) SD (mg/l) CV (%) 
Within-run /Repeatability 1.144 5.89 
Within-Lab 1.140 5.86 
 
The precision of the  FLC assay was acceptable. CV’s of <10% were observed for all 
serum pools and trueness of the control material assigned values verified. 
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3.1.5 Method comparison study 
 
3.1.5.1 Correlation 
 
Correlation describes the level of agreement between two methods and is a very 
important statistical tool that confers reliability of the regression statistics calculated.   
 
For  FLC, a correlation of 0.98 (r = 0.98) was observed indicating good agreement 
between the two methods as shown in figure 3.21. 
 
 
 
Figure 3.21 Method comparison correlation for  FLC 
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For  FLC, a correlation of 0.97 (r = 0.97) was observed indicating good agreement 
between the two methods as shown in figure 3.22. 
 
 
Figure 3.22 Method comparison correlation for  FLC 
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3.1.5.2 Regression statistics 
The  regression equation calculated was y = 1.00x + 0.35; (Sy/x =2.82 mg/l).  The best-
fit line demonstrated a constant error as shown in figures 3.23 and 3.24.   
 
 
Figure 3.23 Deming regression statistics of  FLC 
 
 
The  regression equation calculated was y = 0.93x + 1.71; (Sy/x =4.32 mg/l).  The best-
fit line demonstrated both a constant and proportional error as shown in figure 3.24. 
 
 
 
Figure 3.24 Deming regression statistics of  FLC 
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3.1.5.3 Difference plots (Bland-Altman) 
 
 
Figure 3.25 Difference plot for  FLC  
 
  
Figure 3.26 Difference plot for  FLC  
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The serum creatinine was determined to see whether any of the subjects had renal 
impairment as this is known to affect the FLC values. All the creatinine values were in 
the normal range (44 – 116 µmol/l). Serum protein values were all within the normal 
range (61 – 92 g/L). The serum protein electrophoreses were independently reviewed by 
3 pathologists. Most were normal, with a few polyclonal increases seen, but no definite 
monoclonal bands were detected. One patient had a hypogammaglobulinaemia on serum 
electrophoresis and a raised  FLC and will be followed up. This sample was excluded 
from our analysis. 
 
The 95% reference intervals obtained from our cohort using a non-parametric 
determination on Analyse-it® after elimination of outliers, as well as separate 95% 
reference intervals for Black and Mixed Ancestry subjects is shown in table 3.5. 
 
Table 3.5 95% reference intervals for the various populations as compared to the 
manufacturer’s recommendation 
 MANUFACTURER’S 
RECOMMENDED 95% 
REFERENCE 
INTERVALS 
LOCALLY 
DETERMINED 
95% 
REFERENCE 
INTERVALS  
LOCALLY 
DETERMINED 
95% 
REFERENCE 
INTERVALS IN 
THE MIXED 
ANCESTRY 
POPULATION 
LOCALLY 
DETERMINED 
95% 
REFERENCE 
INTERVALS IN 
THE BLACK 
POPULATION 
Kappa FLC (mg/l) 3.3 – 19.4  6.5 – 23.4  5.98 – 20.36  7.02 – 23.02  
 
Lambda FLC (mg/l) 5.7 – 26.3  8.5 – 30.5  7.77 – 25.83  9.71 – 28.33  
 
FLC ratio 0.26 – 1.2  0.5 – 1.2 0.5 – 1.2  
 
0.5 – 1.3  
 
Appendix 4 shows the graphs obtained for the 95% reference intervals on the Mixed 
Ancestry population. 
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Appendix 5 shows the graphs obtained for the 95% reference intervals on the Black 
population. 
 
In conclusion, our reference values obtained were slightly higher than those 
recommended by the manufacturer. However, most values fell within the manufacturer’s 
limits, and therefore we can accept the manufacturer’s recommended cut-offs in our 
laboratory. 
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Age 
 
The study population included patients from 17 to 70 years as shown in figure 3.28. The 
majority of patients were in the 25 – 54 age groups.  The median age for the whole 
population was 37 years.   
median=37.0  min=17.0  max=70.0
median
   25%-75%
   non-outl ier range
outl iers
10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
AGE
-20
-10
0
10
20
30
40
50
60
70
80
90
N
o 
of
 o
bs
 
 
Figure 3.30 Age distribution of 369 HIV positive patients 
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CD4 counts 
 
CD4 counts were available for 353 (96%) of the 369 patients. The CD4 counts ranged 
from 1 to 1251 cells/mL. The median CD4 count was 287.5. The mean CD4 count 
increased with longer duration of therapy.  
 
Viral load 
 
Viral load results were available for 273 (84%) of the 327 patients on ART. ART 
suppressed viral replication successfully to undetectable levels in 228 (83.5%) patients, 
as measured by viral load detection. The lower limit of detection of the method used is 
357 RNA copies/mL or 2.5 Log copies/mL. An additional 21 patients (7.6%) had a 
detectable viral load, but lower than the stated limit of detection. Only 24 (8.7%) patients 
had viral load results above the detection limit. No viral loads were available for patients 
not on ART. 
 
Table 3.6 shows the median (and range) levels of the various tests performed on the study 
cohort. 
 
Table 3.6 Results median (range) of tests performed on the HIV positive study cohort 
VARIABLE MEDIAN RANGE 
CD4 count (cells/ml) 287.5  1 – 1251  
Total protein (g/l) 80.45  56.1 – 123.4  
Albumin (g/l) 29.45  16.5 – 46.4  
IgG (g/l) 22.12  9.57 – 112.9  
IgA (g/l) 3.62  0.25 – 22.63  
IgM (g/l) 1.4  0.4 – 89.0  
Creatinine (mol/l) 61.0  29.0 – 204.0  
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Gamma fraction 
 
The gamma fraction as quantified using the Paragon™ Electrophoresis System and 
Appraise™ Densitometer System both from Beckman Coulter and varied in size from 8.2 
to 80.6 g/L with a median value was 24.09 g/L.  Although the range of values is wide, 
most patients had gamma fractions under 30 g/L. Only 82 (22%) of electrophoresis 
results had a gamma fraction of more than 30 g/L and 15 (4.9%) a gamma fraction of 
more than 40g/L. However, if the upper limits of the reference range (22 g/L) is 
considered, only 143 (39%) patients fall within the reference range. 
 
Table 3.7 shows the median (range) values of  and  FLC’s and the FLC ratio 
determined in the study cohort. 
 
Table 3.7 FLC values in the HIV positive study cohort 
 
VARIABLE MEDIAN RANGE 
Kappa FLC (mg/L) 19.6  5.59 – 387.0  
Lambda FLC (mg/L) 22.3  9.28 – 286.0  
FLC ratio 0.85 0.13 – 3.28  
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3.3.2 Correlations of FLC’s with various variables 
 
The Spearman rank correlation coefficient for non-parametric data was used to compare 
continuous variables to FLC’s.  Kappa and λ FLC’s and FLC-ratio were compared to 
numerous variables.  These included age, CD4+ count, viral load, duration of disease, 
total protein values, albumin levels, gamma fraction levels, immunoglobulins levels and 
creatinine levels. Spearman correlations are not influenced by outliers and correlations 
are from -1 to +1, where +1 indicates a positive relationship and -1 a negative 
relationship.  Values close to zero indicate no relation.  The p-value tests the hypothesis 
that r = 0.  A p < 0.05 rejects the correlation and is significant. 
 
Age 
 
Kappa and λ FLC and FLC-ratio were not significantly influenced by age (p= 0.8, p=0.6 
and p=0.18 respectively).  
 
CD4+ count 
 
Both κ and λ FLC showed significant inverse correlation with the CD4+ count with the 
lowest CD4+ counts showing high FLC levels (p < 0.05 for both). However FLC–ratio 
was not significantly influenced by CD4+ count (p = 0.18).  This is shown in Appendix 6 
 
Viral load 
 
We found a positive correlation between viral load and κ and λ FLC (p < 0.05 for both).  
However, the FLC-ratio was not influenced by viral load (p = 0.65). 
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Duration of disease 
 
Kappa and λ FLC and FLC-ratio were all significantly negatively influenced by duration 
of disease.  (p < 0.05 for κ and λ FLC and p = 0.05 for FLC-ratio). This is shown in 
Appendix 7. 
   
Total protein 
 
A significant positive correlation was found between κ, λ FLC and FLC-ratio and total 
protein values (p < 0.05 for all).  
 
Albumin 
 
A significant negative correlation was found between albumin levels and κ and λ FLC. (p 
< 0.05). However there was no significant correlation between albumin levels and FLC-
ratio (p = 0.6).  
 
Gamma fraction 
 
A significant positive correlation was found between the gamma fraction and  
 and λ FLC and FLC-ratio.  (p < 0.05 for all). This is shown in Appendix 8.  
 
IgG  
 
A significant positive correlation was found between the IgG level and  
 and λ FLC and FLC-ratio.  (p < 0.05 for all). This is shown in Appendix 9.  
 
IgA and IgM 
 
A significant positive correlation was found between the IgA level and  
 and λ FLC.  (p < 0.05 for both). However the correlation between IgA and FLC-ratio 
was not significant (p = 0.1).  A similar picture was seen for IgM. 
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Creatinine 
 
A slight positive correlation was found between the creatinine levels and  
 and λ FLC.  (p = 0.01 and p = 0.28 respectively). However, significantly positive 
correlation was found between creatinine levels and the FLC-ratio (p < 0.05).  
 
Table 3.8 shows the correlation of  and  FLC’s and FLC ratio to the various variables. 
 
Table 3.8 Correlation of  and  FLC’s and FLC ratio to various variables (p<0.05 
significant) 
 
VARIABLES KAPPA FLC LAMBDA FLC FLC RATIO 
 Spearman 
correlation 
(r-value) 
p-value Spearman 
correlation 
(r-value) 
p-value Spearman 
correlation 
(r-value) 
p-value 
Age -0.01 0.80 0.03 0.6 -0.07 0.18 
CD4 count -0.34 <0.05 -0.34 <0.05 -0.07 0.18 
Viral load 0.21 <0.05 0.22 <0.05 0.03 0.65 
Duration of 
disease 
-0.43 <0.05 -0.35 <0.05 -0.10 0.05 
Total protein 0.43 <0.05 0.37 <0.05 0.17 <0.05 
Albumin -0.17 <0.05 -0.21 <0.05 0.03 0.60 
Gamma 0.58 <0.05 0.51 <0.05 0.24 <0.05 
IgG 0.66 <0.05 0.61 <0.05 0.23 <0.05 
IgA 0.19 <0.05 0.29 <0.05 -0.09 0.10 
IgM 0.37 <0.05 0.41 <0.05 0.00 0.96 
Creatinine 0.13 0.01 0.06 0.28 0.15 <0.05 
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3.3.3 Relationships of FLC’s with non-continuous variables 
 
ANOVA analysis was used to correlate κ and λ FLC and FLC-ratio to non-continuous 
variables, such as gender, ethnicity, stage of disease, use of ART’s and the presence of an 
abnormal serum protein electrophoresis.  The data was first log transformed to minimize 
the effect of outliers on the results.  The F-test and the Mann-Whitney U test were used.  
They test the hypothesis that the means are equal.  A p-value of < 0.05 rejects the 
hypothesis and is significant. 
 
Gender 
 
Kappa and λ FLC and FLC-ratio were slightly higher in males than in females.  This was 
only significant for κ FLC (p = 0.02), but not significant for λ FLC (p = 0.13) and FLC 
ratio (p = 0.45).   
 
Ethnicity 
 
No significant difference was found in κ and λ FLC and FLC ratio between those of 
mixed ancestry and black (p = 0.25, p = 0.16 and p = 0.26 respectively).   
 
Stage of disease 
 
There seemed to be an upward trend between stage of disease and κ and λ FLC (p = 0.06) 
and (p < 0.01) respectively.  However, there was no significant trend between FLC ratio 
and stage of disease (p = 0.37).  This is shown in Appendix 10. 
 
Use of ART’s 
 
A strongly significant difference was seen between κ FLC values in patients taking 
ART’S compare to those not (p < 0.01).  Those taking ART’S had lower levels of κ FLC. 
The same was found when comparing these two groups with λ FLC values (p < 0.01). 
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However, FLC ratio was not significantly affected by ART use (p = 0.98). This is shown 
in Appendix 11. 
 
 
Immunofixations for abnormal serum protein electrophoresis 
Kappa and FLC and FLC ratio values differed significantly when an abnormal band was 
found on serum protein electrophoresis (p < 0.01for all). This is shown in Appendix 12.   
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SECTION IV: DISCUSSION 
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4.1 METHOD VALIDATION 
It is a standard process to validate a new method before its introduction as part of good 
laboratory practice.  Method validation focuses on analytical errors and the impact of 
these errors on the interpretation of the test. 
 
Dr Westgard refers to method validation simply as “error assessment”.  The focus is on 
analytical errors and how these errors impact on the interpretation of a test.  While a 
comparison of method experiment can reveal the different type of errors, there are 
specifically designed experiments for each one of them. (Westgard. 2008) Random errors 
can be detected using replication studies, constant errors using interference studies and 
method comparison studies and proportional errors using recovery, linearity and method 
comparison studies. 
 
Serum FLC assays are not without problems (Tate et al. 2009).  Experienced staff, proper 
laboratory techniques, and well maintained equipment is important for serum FLC assays 
(Davids et al. 2010).  Batch to batch inconsistency (Davids et al. 2010), antigen excess 
causing underestimation of high results (Davids et al. 2010; Bosmann et al. 2010; Daval 
et al; 2007), risk of overestimation and overestimation with dilutions (Tate et al. 2007) 
and polymerization of FLC can lead to false overestimation (Tate et al. 2003; Bradwell et 
al. 2001; Abrahams et al. 2002).   Measurements of κ and λ FLC should be performed in 
the same laboratory with the same analyzer (Tate et al. 2003), because different results 
may be obtained with different analyzers, thus each lab should estimate its own local 
reference ranges. (Briand et al. 2010; Beetham et al. 2007). 
 
We found κ and λ FLC’s to be linear within the manufacturer’s recommended range 
using both linearity fluid and pooled serum obtained from routine samples received in the 
chemical pathology laboratory.  Recovery studies were performed to estimate the effects 
of specific materials on the accuracy of the method or systematic error.  The average  
recovery was excellent, but we found the  recovery to be only 40.36%, showing a large 
proportional error, probably due to matrix effect. We consulted the Binding Site about 
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this result, but were told that as the rest of the method validation study was acceptable, 
we could accept this as matrix effect and introduce the test. 
 
Interferences studies were performed to estimate constant error caused by Hb due to 
haemolysis, bilirubin, rheumatoid factor and triglycerides interfering with the assay.  
When studying the effect of haemolysis on  FLC results using both low and high pools, 
we found that results were within the 10% allowable error, but the κ FLC high pool was  
out of the 10% allowable laboratory error, most likely due to a random error. Again we 
contacted the Binding Site and were told we could introduce the test, as the results were 
within a 20% allowable error. Bilirubin, rheumatoid factor and triglyceride interference 
studies did not exceed the 10% or 20% allowable error for κ and λ FLC. In fact, all the 
results were within the 10% allowable error, showing minimal interference for both κ and 
λ FLC. 
 
Imprecision studies were performed using the CLSI EP-15 protocol to establish the 
amount of random error (Chesher. 2008).  The precision of κ FLC was acceptable.  
Trueness of the assigned control material was verified and acceptable CV’s of <10% 
were observed for all  serum pools.  The precision of λ FLC was acceptable.  When 
trueness of the assigned control material was verified, CV’s of <10% were observed for 
all serum pools. 
 
Method comparison studies estimates bias, for example the inaccuracy or systematic error 
of a method.  We compared the results obtained on our Beckman IMMAGETM analyzer 
to those obtained on the same instrument at a local private laboratory. Correlation studies 
between the two laboratories for κ and λ FLC showed a correlation of 0.97 (r=0.97) and 
0.98 (r = 0.98) respectively, indicating an excellent agreement between the two methods.  
The λ regression equation calculated was y = 1.00 x+ 0.35 with the best-fit line 
demonstrating a constant error.  The κ regression equation was y = 0.93 x+ 1.71 with the 
best-fit line demonstrating both a constant and proportional error. 
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4.2 LOCAL FLC REFERENCE RANGES 
 
Serum FLC assays are an important diagnostic, prognostic, therapeutic marker and 
management tool in a variety of diseases such as MM with its phenotypes(Davids et al. 
2010; Kyrtsonis et al. 2007; van Rhee et al. 2007), NSMM (Drayson et al. 2001), light 
chain disease (Bradwell et al. 2003; Katzmann et al. 2006) , MGUS (Rajkumar et al. 
2005), solitary bone plasmacytoma (Dingli et al. 2006), smouldering myeloma 
(Dispenzieri et al. 2008), Al amyloidosis (Katzman et al. 2005), Waldenström’s 
macroglobulinaemia (Izykson et al. 2008; Leleu et al. 2008)] and chronic lymphocytic 
leukemia (Martin et al. 2007).  
 
 
 Although manufacturers 95% reference intervals have been established (Katzmann et al. 
2002), we decided to establish our own reference intervals, as part of good laboratory 
practice. Besides this being part of good laboratory practice, we also felt it necessary to 
establish local reference intervals, as the manufacturers’ reference intervals were 
established mainly on an older Caucasian population. Our study population age and race 
distribution is not the same as we studied mainly younger black and mixed ancestry 
subjects.  
 
Tate and Pattenden described in their respective studies that different FLC values were 
obtained on different analyzers when analyzing the same sample (Tate et al. 2007; 
Pattenden et al. 2007). Therefore, laboratories should validate FLC reference intervals on 
their assay using at least 20 normal samples to confirm that at least 90% of the sample 
values fall within the recommended reference interval for FLC concentration and ratio 
(Tate et al. 2009). 
 
Several studies have shown differences in the prevalence of MGUS and MM in various 
ethnic groups. In a study by Weiss et al was it reported that FLC values are higher in 
blacks with MGUS than in Caucasians (Weiss et al. 2011). The prevalence of MGUS and 
MM are higher in African Americans compared to Caucasians with Asians having the 
lowest prevalence, which points to a definite difference in ethnic and genetic factors 
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contributing to the development of MGUS and MM (Landgren and Weiss. 2009). 
Katzmann et al described an increase in FLC concentration with increasing age, with a 
dramatic increase in those older than 80 years. This has been postulated to be due to renal 
impairment associated with age. This is supported by the fact that the κ/λ FLC ratio does 
not increase with age-dependant increases in FLC (Katzmann et al. 2002). Therefore we 
postulated that FLC levels may be higher in our population due to their ethnicity, but as 
their age was younger, the levels would be less influenced by age-related decline in renal 
function. 
 
Our study population was younger with a median age of 37 years and 66% were of black 
ethnicity. We used 120 healthy HIV negative subjects consisting of healthy blood donors 
and healthy control subjects partaking in another study. The demographics were similar 
to our study population with an age range of 19 – 60 years (median 36.5 years). The 
racial distribution was as follows:  12 (10%) Caucasians, 48 (40%) mixed ancestry and 
60 (50%) blacks. Serum creatinine was determined to exclude renal impairment as this 
affects the FLC values (Katzmann et al. 2002). All the creatinine values fell within the 
normal range of 44 – 116 µmol/l. We also performed serum protein electrophoresis on all 
subjects to exclude abnormal FLC values due to undiagnosed plasma cell dyscrasias. 
 
When mixed ancestry and black subjects were analyzed separately, data was first log-
transformed and then analyzed. The local reference interval of the black subjects in our 
cohort is in agreement with results from Weiss et al that showed that black MGUS 
patients had higher FLC levels (Weiss et al. 2011). Our reference intervals were slightly 
higher than those recommended, however as most of our values fell within the 
manufacturers limits, it was decided to accept these cut-offs in our study after 
consultation with the Binding Site, as most results still fell within the recommended cut-
offs.  
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4.3 FREE LIGHT CHAINS IN HIV POSITIVE SUBJECTS 
 
The main purpose of this study was to investigate whether FLC’s as a marker of B-cell 
dysfunction are increased in subjects with HIV.  FLC are known to be markers of B-cell 
dysfunction and as subjects with HIV are described to have B-cell abnormalities, we 
hypothesized that FLC levels and FLC ratio will be abnormal in HIV-infected 
individuals. Despite B-cell dysfunction being described in HIV (De Milito. 2004; Sodora 
and Silvestri.  2008; Moir and Fauci. 2009; Moir and Fauci. 2008; Caggi et al. 2008; 
Virgin and Walker. 2010; Bussmann et al. 2009; Appay and Sauce. 2008), there is a 
paucity of literature available on FLC levels in HIV (Landgren et al. 2010).  
 
Our cohort consisted of 369 HIV positive subjects, many of whom were on HAART. The 
cohort was judged to be representative of the patients attending clinics for ART and 
disease management in the Western Cape.  The study population included 127 males 
(34%) and 242 females (66%).  There were twice as many females than males that were 
enrolled in the study, but is in agreement with what is expected, based on recently 
available HIV prevalence rate estimated for the Western Cape (Department of Health. 
2007). The Human Science Research Council (HSRC) report also cited a higher 
prevalence in females in South Africa (13.3% in females vs 8.2% in males) 
(www.hsrcpress.ac.za). The study population age ranged from 17 to 70 years, with most 
between 25 to 54 years.  The median age for the whole study population was 37 years, 
with males being significantly older than females.  The peak age prevalence of HIV 
infection in South Africa is between the ages of 25 and 34 years for females and 30 to 39 
years for males.  The age difference is therefore expected.  The mean age of patients 
attending the clinic would thus be expected to be slightly older than the peak prevalence 
age, due to the time it takes for diseases progression before treatment becomes necessary 
(www.hsrcpress.ac.za). 
 
The population included patients from all the major ethnic groups resident in the Western 
Cape. The majority of patients were black (245, 66%), with 27% (98) being of mixed 
ancestry.  Only 6 (2%) of patients in the study population was of Caucasian background, 
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6 (2%) of the patients in the study were of unknown race and 14 (4%) were of other 
ethnic background. The largest population group in the Western Cape is of mixed 
ancestry (54%), followed by Blacks (27%), Caucasians (18%) and Indian/Asians (1%) 
(www. Statssa.gov.za).  The prevalence rates of HIV differs between population groups 
in South Africa (Blacks 13,3%, Mixed Ancestry 1,9% Indian/Asian 1,6% and Whites 
0,6%) (www.hsrcpress.ac.za).   The ethnic composition of patients attending HIV clinics 
in the Western Cape would therefore be expected to approximately be 76% Blacks, 22% 
Mixed Ancestry, 2% Caucasian and less than 1% Asian/Indian.  Our study population is 
therefore representative of the population groups expected to be seen at the clinics. 
 
The clinical stage of disease was documented for only 238 (64.5%) of patients.  
According to the WHO guidelines for HIV, 8 (3%) patients had stage I, 46 (19%) patients 
had stage II, 129 (54%) patients had stage III and 55 (23%) patients had stage IV HIV 
infection.  Tuberculosis (TB) is endemic in the Western Cape with an incidence rate of 1 
041/100 000 of the population reported in 2005 (Bradshaw et al. 2005).   Of the 68 
patients in our cohort having co-existing medical conditions, 47 (69%) were being treated 
for TB. 
 
According to Moir and Fauci, decreased CD4+ count and not viral load, leads to increased 
immature B-cells in HIV (Moir and Fauci. 2008). CD4 counts were available for 353 
(96%) of the 369 patients and ranged from 1 to 1251 cells/mL with a median value of 
287.5 cells/mL. The mean CD4 count increased significantly with increased duration of 
ART. Both κ and λ FLC showed a significant inverse correlation with CD4+ counts with 
the lowest CD4+ counts having higher FLC levels.  This correlation supports the theory of 
B-cell dysfunction as a feature of HIV pathogenesis and may be a valuable marker of 
potential disease progression.  
 
Viral load results were available for 273 (84%) of the 327 patients on ART. Ideally, viral 
loads should be decreased to < 400 RNA copies/ml with effective ART. ART suppressed 
viral replication successfully to undetectable levels in 228 (83.5%) patients, as measured 
by viral load detection. The lower limit of detection of the method used is 357 RNA 
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copies/mL or 2.5 Log copies/mL. An additional 21 patients (7.6%) had a detectable viral 
load, but lower than the stated limit of detection. Only 24 (8.7%) patients had viral load 
results above the detection limit. We found a positive correlation between viral load and 
κ and λ FLC.  However FLC-ratio was not influenced by viral load which supports the 
well described finding of polyclonal B-cell activation in HIV infection. 
 
The serum total protein values ranged from 56.1 to 123.4 g/L with a median value of 
80.45 g/L, which is indicative of some of these subjects having increased protein levels, 
most likely due to increased gamma fractions. Albumin levels were quantified using the 
Paragon™ Electrophoresis System and Appraise™ Densitometer System both from 
Beckman Coulter and ranged from 16.5 to 46.4 g/L, with a median of 29.45 g/L. Albumin 
is a negative acute phase reactant and decreases in the acute phase of infection.  We 
found a significantly negative correlation between albumin, and κ and λ FLC levels, 
which indicates that B-cell activation and decreased albumin occurs in the acute phase of 
HIV infection.  Again there was no significant correlation between albumin and FLC 
ratio, pointing to polyclonality.   
 
The gamma fraction was also quantified using the Paragon™ Electrophoresis System and 
Appraise™ Densitometer System and varied in size from 8.2 to 80.6 g/L with a median 
value was 24.09 g/L.  Although the range of values is wide, most patients had gamma 
fractions under 30 g/L. If the upper limit of the reference interval (22 g/L) is considered, 
143 (39%) patients fell within the reference range. A strong positive correlation was 
found between the gamma fractions and κ and λ FLC values and κ /λ FLC ratio. As the 
gamma fraction is most likely indicative of increased immunoglobulins, this correlation 
again points to B-cell hyperactivity. 
 
As the gamma fraction was determined densitometrically and is therefore more of a 
subjective measurement, the IgG value which is determined nephelometrically, is more 
reliable. IgG levels varied from 9.57 – 112.9 g/L with a median value of 22.12 g/L. A 
strong positive correlation was found between IgG levels and κ and λ FLC values and κ 
/λ FLC ratio. This is self-explanatory, as FLC levels will be increased with increased 
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immunoglobulin synthesis and these were thus expected. A similar positive correlation 
was found between IgA and IgM levels and κ and λ FLC values, but not for κ /λ FLC 
ratio, pointing to polyclonal IgA and IgM synthesis. 
 
As FLC are known to be influenced by renal function, we determined creatinine levels 
and these varied from 29.0 – 204.0 µmol/L with a median value of 61.0 µmol/L. A 
slightly positive, but still statistical significant correlation was found between creatinine 
and κ and λ FLC values. This is to be expected as FLC are filtered and excreted by the 
kidney, so higher creatinine levels indicating decreased renal function would result in 
higher FLC values. Though the literature describes these subjects as having FLC ratio 
values within the reference intervals (Katzmann et al. 2002), we found a significant 
positive correlation between FLC ratio and creatinine   levels in our study. 
 
FLC values and FLC ratio were also correlated to non-continuous variables after log 
transformation.   Kappa and λ FLC values were found to be slightly higher in males than 
in females in our study cohort; however 34% of the cohort was males who were older, 
which perhaps attributed to this. As expected in HIV, some of our subjects with HIV had 
high κ and λ FLC values with κ FLC ranging from 5,59 – 387,0 mg/L with a median of 
19,6 mg/L and λ FLC ranging from 9,28 – 286,0 mg/L with median of 22,3 mg/L.   
 
When correlating κ and λ FLC and κ/ λ FLC ratio to age, no significant correlations were 
found.  This is contradictory to what is found in the literature which shows increased 
values with age most likely due to decreasing renal function (Katzmann et al. 2002). No 
significant difference was found in κ and λ FLC and FLC ratio between those of mixed 
ancestry and Black origin. 
 
Of great significance was the statistically significant inverse correlation that was found 
between CD4+ counts and κ and λ FLC levels.  Traditionally, HIV has been associated 
with CD4+ count abnormalities and cellular immunity dysfunction (Schnittman et al. 
1986; Lane et al. 1983).  Recent publications have shown marked B-cell dysfunction in 
HIV and this may be due to the T-cell effect on B-cell function (Caggi et al. 2008; de 
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Milito. 2004; Moir and Fauci. 2008; Sodora and Sivestri. 2008; Moir and Fauci. 2009; 
Virgin and Walker. 2010; Bussmann et al. 2009; Appay and Sauce. 2008). However the 
FLC ratio was not influenced by CD4+ count which points to polyclonal B-cell activation. 
These results support the finding that T-cells have an important influence on B-cell 
function. 
 
Another exciting finding was the significant positive correlation between viral load and κ 
and λ FLC levels, but not the ratio.  This again points to increasing B-cell dysfunction 
with disease severity.  The fact that FLC ratio is not significantly influenced by CD4+ and 
viral load, points to polyclonal B-cell dysfunction.   
 
When examining the stage of disease and its correlation with κ and λ FLC values and 
FLC ratio, a definitive upward trend was seen between these two variables. This was only 
evident from stage 2 onward, but it must be noted that only 8 subjects had stage 1 
disease. There was no correlation between FLC ratio and stage of disease, again pointing 
to polyclonality. 
 
Kappa and λ FLC as well as FLC ratio negatively and significantly influenced by 
duration of disease, most likely as a result of the commencement of treatment in these 
subjects with recovery of B-cell dysfunction. 
 
As mentioned previously, this cohort was used in a previous study to determine the 
prevalence of monoclonal band in HIV positive subjects in our local population, so serum 
protein electrophoresis was performed on the subjects (Jansen van Vuuren et al. 2010). 
Immunofixation electrophoresis was performed on 100 (27%) of the 369 cases for an 
abnormal pattern on serum protein electrophoresis. A visible band was seen in only 27 
(27%) of these cases and no visible bands were seen in 73 (73%).  The majority of 
immunofixations were performed due to a large gamma area where the presence of a 
visible band could not be excluded.  Monoclonal bands were identified in 12 patients 
(3.2% of the total study population) after immunofixation and oligoclonal bands in a 
further 14 patients (3.8%). When correlating κ and λ FLC values and FLC ratio to the 
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presence of an abnormal band in serum protein electrophoresis, the presence of an 
abnormal band was associated with significantly higher κ and λ FLC values and FLC 
ratio. This supports the fact that FLC values are increased in conditions associated with 
an abnormal serum protein electrophoresis, such as plasma cell dyscrasias. 
 
When correlating the use of ARV’S with κ and λ FLC values, a significant difference was 
found between those taking ARV’S and those not. Kappa and λ FLC values were 
significantly higher in the group not on treatment. This is to be expected and supports the 
theory that ARV’S improve B – cell dysfunction in HIV positive subjects. No correlation 
was found between the use of ARV’S and FLC ratio, again supporting polyclonality. 
There are several limitations to the study: 
 
Firstly, albumin and gamma fractions were determined densitometrically. This technique 
is subjective and dependant on technologist expertise, however most of the serum protein 
electrophoreses were performed by the same technologist, so there should have been 
continuity. However, IgG values were determined and they correlated well with the 
gamma fractions. 
 
Secondly, creatinine was used as a marker of renal function. However, creatinine is not a 
reliable marker of renal function and only increases late when up to 50% of renal 
function been lost. A better test of renal function would have been a creatinine clearance, 
but this is a cumbersome test, requiring a 24-hour urine sample. Cystatin C has also been 
described as a good marker of renal dysfunction (Katzmann et al. 2002), but 
unfortunately the test is not available in our laboratory, so we had to rely on creatinine.  
 
Thirdly, viral loads, CD4+ counts and immunofixation results were not available for all 
389 subjects.  
 
Fourthly, only 8 subjects had stage I disease and therefore the results correlating FLC 
values and FLC ratio to stage of disease are unreliable for stage I. 
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Finally, three years after the initial study (Jansen van Vuuren et al. 2010) was performed 
on this cohort, we have not yet received one follow-up sample on abnormal results, 
despite numerous communications to the clinicians. This signifies a total loss of follow-
up in this cohort. Landgren et al. described FLC as a prognostic marker in HIV for future 
malignancies (Landgren et al. 2010).  However, we will not be able to verify this in our 
cohort due to the loss of follow-up.  
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SECTION V: CONCLUSION 
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CONCLUSION 
 
Method validation of the FLC assay on the Beckman IMMAGE® was found to be 
acceptable for our study and introduction for routine use in our laboratory is advocated. 
 
Although we postulated that the reference intervals in our population would differ from 
the manufacturers’ recommended reference intervals due to the difference in study 
population, we found that we could accept the recommended reference intervals in our 
population. 
 
As expected, FLC which is a marker of B-cell dysfunction was increased in subjects with 
HIV.  Traditional markers of HIV severity, namely CD4+ T-cell count and viral load 
correlated with these levels. The use of ARV, which is known to improve B-cell 
dysfunction in HIV, led to decreased FLC levels indicating that the B-cell function is 
indeed improved in these subjects.  
 
We would like to have studied the future effects of these raised and abnormal FLC values 
in these subjects to see if they had a worse prognosis and maybe higher incidence of B-
cell malignancies in the future, but as mentioned in the limitations of this study, most of 
this cohort seems to be unfortunately lost to follow-up. 
 
A future study is already being planned following on from this, where we will examine at 
FLC values in a cohort of newly diagnosed treatment-naïve HIV positive subjects. We 
will then follow these subjects up to see if they indeed have a worse prognosis and further 
study the effect of ART on the FLC values. 
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ADDENDUM A:  
CLINICAL DATA: Study on monoclonal gammopathies in patients with HIV 
Study patient identification number_______________ 
Date:_________________ 
Demographics: 
Age: _________________   
Gender:  M  /  F 
Disease stage: 
WHO clinical stage:_______________________________________________ 
Latest 
- CD4________________________  Date__________________________ 
- Viral load____________________ Date__________________________ 
Other disease diagnosis:  (pls indicate diagnosis and treatment where appropriate)   
- TB:  Current/ Previous_______________________________________________________ 
Treatment:____________________________________________________________ 
- Auto-immune disease: Diagnosis  _______________________________________________ 
 Treatment: ___________________________________________________________ 
- Malignancy:  Diagnosis ________________________________________________________ 
 Treatment: ___________________________________________________________ 
- Viral hepatitis : Diagnosis ____________________________________________________ 
 Treatment: ___________________________________________________________ 
- Other: Diagnosis ____________________________________________________________ 
 Treatment: ___________________________________________________________ 
 
Treatment: 
HAART:  Y / N  
Date started: _______________________ 
1st /2nd regimen: 
Previous regimen if applicable: _________________________________________________ 
Current regimen: Drugs: (Circle pls) 
d4T 3TC EFV Other _____________ 
AZT ddi NVP 
ABC  KLT 
TDF  SQV 
  RTV 
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Person filling in this form: 
Name _______________________ Signature__________________ 
ADDENDUM B:  
DEELNEMERS INLIGTINGSBLAD EN TOESTEMMINGSVORM  
Titel van navorsingsprojek:  
Monoklonale pieke in pasiënte met HIV: Die prevalensie en assosiasie met stadium van 
siekte, chroniese antigeen stimulasie en die effek van antiretrovirale terapie.  
 
En 
 
Vergelyking van die sensitiwiteit en spesifisiteit van agarose gel elektroforese, kapillêre 
sone elektroforese en serum vry ligte ketting analise in die diagnose van monoklonale 
gammopatie in pasiënt met HIV. 
 
Verwysingsnr: 
Hoofnavorser: Dr A Zemlin 
Adress: Afdeling Chemiesie Patologie, NHLS, Tygerberg Hospitaal. 
 
 U word genooi om deel te neem aan ‘n navorsingsprojek. Lees asseblief hierdie inligtingsblad op 
u tyd aangesien die besonderhede van die navorsingsprojek daarin verduidelik word. 
 
 Hierdie navorsingsprojek is deur die Komitee vir Mensenavorsing van die Universiteit Stellenbosch 
goedgekeur en sal uitgevoer word volgens die etiese riglyne en beginsels van die Internasionale 
Verklaring van Helsinki en die Etiese Riglyne vir Navorsing van die Mediese Navorsingsraad 
(MNR). 
 
 Die navorsingsprojek behels die volgende: 
Die doel van die projek is om te kyk na die antiliggaamprofiel van pasiënte met HIV infeksie op 
serum elektroforese. Ons is veral geinteresseerd in die teenwoordigheid van monoklonale pieke. 
Dit is die teenwoordigheid van ‘n band op die serum elektroforese wat aanduidend is van ‘n 
enkele tipe antiliggaam wat deur ‘n kloon van antiliggaamproduserende selle gemaak word. 
Elektroforese is 'n metode wat gebruik word om proteine in die bloed van mekaar te skei. Die 
monoklonale pieke kom ook voor in pasiënte wat nie HIV infeksie het nie waar dit dikwels dui op 
die teenwoordigheid van ‘n limfoom of veelvuldige miëloom (‘n kanker van 
antiliggaamproduserende selle) of die ontwikkeling daarvan voorgaan. Hierdie pasiënte word 
noukeurig opgevolg vir die ontstaan van die toestande. Monoklonale pieke kom meer algemeen 
voor wanneer ‘n persoon HIV infeksie het, maar die betekenis daarvan is nie duidelik nie. Dit mag 
moontlik net die gevolg wees van die immuunrespons teen die virus of mag moontlik ‘n risiko 
wees om limfoom of veelvuldig miëloom te ontwikkel. Ons wil die betekenis van die monoklonale 
pieke verder ondersoek om riglyne daar te stel vir die hantering en opvolg daarvan. 
  
 Dieselfde monsters sal ook met verskillende metodes (agarose gel elektroforese, kapillêre sone 
elektroforese en serum vry ligte kettings) geanaliseer word om vas te stel watter metode die 
mees sensitief en spesifiek is sodat pieke nie gemis word nie, 
maar onnodige verdere ondersoeke nie gedoen word nie. Hierdie data sal ook gepubliseer word 
as 'n aparte studie. 
 
 Die studie behels die neem van bloed (10ml/ 2 teelepels) en ‘n uriene monster(100ml / halwe 
koppie). 
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 Indien daar wel ‘n monoklonale piek teenwoordig is sal u die nodige verdere ondersoeke 
aangebied word om die teenwoordigheid van limfoom of plasma sel tumore uit te skakel. Dit mag 
moontlike X-strale, CT skandering of beenmurgbiopsie behels. Dit sal met u bespreek word en 
toestemming verkry word vir die ondersoeke indien nodig. Die piek sal ook 6 maandeliks of 
jaarliks opgevolg word met ‘n bloed of uriene monster. 
 
 Alle pasiente met HIV infeksie wat opvolg word by die Tygerberg Infeksie Siekte Kliniek word 
genooi om aan die studie deel te neem. 
 
 Deelname is vrywillig en dit staan u vry om deelname te weier. U mag ook enige tyd aan die 
projek onttrek, selfs al het u ingestem om deel te neem. 
Deelname sal nie die behandeling wat u ontvang beïnvloed nie. 
 Die voordeel vir u om aan die studie deel te neem is dat die teenwoordigheid van ‘n monoklonale 
piek geïdentifiseer word en dat u opgevolg sal word.  
Die risiko’s verbonde aan deelname behels die normale risiko’s van bloedtrek, nl  
- pyn by die area waar bloed getrek word 
- bloeding in en rondom die area waar bloed getrek is of hematoom vorming. 
Indien verdere opvolg ondersoeke nodig is sal die prosedure en risiko’s aan u verduidelik en u 
toestemming verkry word. 
 
 Al die inligting wat versamel word sal vertroulik hanteer word. Dit sal gebruik word in ‘n 
publikasie en tesis, maar die identiteit van deelnemers sal anoniem bly. Die mediese personeel 
wat u inligting versamel en die navorsers wat dit prosesseer sal toegang hê tot die inligting. 
 
 U sal nie betaal word om deel te neem aan die projek nie, maar dit  sal u ook niks kos nie. 
 
 Enige vrae kan aan die dokter wat u behandel gerig word of die navorsers kan gekontak word by 
die bogenoemde nommers. 
 
 
Verklaring deur deelnemer  
 
Ek_____________________________________________________ stem in om deel te neem aan die 
navorsingsprojek getiteld:  
Monoklonale pieke in pasiënte met HIV: Die prevalensie en assosiasie met stadium van siekte, chroniese 
antigen stimulasie en die effek van antiretrovirale terapie.  
En 
Vergelyking van die sensitiwiteit en spesifisiteit van agarose gel elektroforese, kapillêre sone elektroforese 
en serum vry ligte ketting analise in die diagnose van monoklonale gammopatie in pasiënt met HIV. 
 
 Ek verklaar dat ek bogenoemde inligting gelees het of dit aan my verduidelik is en dat ek dit 
verstaan.  
 Ek het die geleentheid gehad om vra te stel en dit is bevredigend beantwoord. 
 Ek verstaan dat deelname an die projek vrywillig is en dat daar geen druk op my geplaas is om 
deel te neem nie en dat ek enige tyd mag onttrek. 
 
Geteken te_____________________________op_____________________________ 
 
Handtekening van deelnemer: __________________   Getuie:_____________________ 
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Verklaring deur navorser: 
 
Ek _____________________________ verklaar dat ek die inligting in hierdie dokument aan bogenoemde 
pasient verduidelik, hom aangemoedig om vra te vra en is tevrede dat hy al die aspekte van die 
navorsingsprojek verstaan. 
 
Geteken te_____________________________op_____________________________ 
 
Handtekening van navorser/klinikus:________________ Getuie:_____________________ 
 
Verklaring deur tolk (indien gebruik)  
 
Ek  __________________________ verklaar dat ek bogenoemde navorser bygestaan het om die inligting 
aan bogenoemde deelnemer te verduidelik  in Xhosa. 
 Ons het hom aangemoedig om vrae te vra en voldoende tyd gebruik om dit te antwoord.  
 Ek het ‘n feitilike korrekte weergawe oorgedra van dit wat aan my vertel is.. 
 Ek is tevrede dat die deelnemer die inhoud van die document ten volle verstaan. 
 
Geteken te_____________________________op_____________________________ 
 
Handtekening van tolk:_____________________Getuie:___________________________ 
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PARTICIPANT LEAFLET AND CONSENT FORM. 
 
Title of research project:  
Monoclonal gammopathy in patients with HIV: The prevalence and association with stage of 
disease, chronic antigen stimulation and the effect of HAART. 
 
And 
 
A comparison of the sensitivity and specificity of agarose gel electrophoresis, capillary zone 
electrophoresis and serum free light chain analysis in the diagnosis of monoclonal 
gammopathy in patients with HIV. 
 
 
Reference nr: 
Principle investigator: Dr A Zemlin 
Address: Division of Chemical Pathology, NHLS, Tygerberg Hospital 
 
 You are being invited to take part in a research project. Please take some time to read the 
information here, which will explain the details of this project. 
 
 This study has been approved by the Committee for Human Research at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the International 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medial 
Research Council (MRC) Ethical Guidelines for Research. 
 
 The research project is about the following: 
The goal of the research project is to look at the antibody profile of patients with HIV infection on 
serum electrophoresis. Electrophoresis is a method used to separate different proteins. We are 
especially interested in the presence of monoclonal bands/peaks. That is the presence of a band 
on the serum electrophoresis that indicates a single type of antibody that is produced by clone of 
an antibody producing cells. The monoclonal peak is also found in patients who do not have HIV 
infection, where it often indicates the presence of lymphoma or multiple myeloma (a cancer of 
antibody producing cells) or precedes the development of it. A monoclonal peak is followed up 
carefully for the development of these conditions. Monoclonal peaks are more common in 
patients with HIV infection, but the significance is not clear. It may be the result of the immune 
response to the virus, or it may indicate a risk for developing lymphoma or multiple myeloma. We 
want to investigate the significance of these monoclonal peaks further to establish guidelines for 
their management and follow-up. 
  
 The same specimens will also be analyzed with different methods (agarose gel electrophoresis, 
capillary zone electrophoresis and serum free light chains) to determine which method is the 
most sensitive and specific. This is important to make sure that the presence of peaks are not 
missed or on the other hand, unnecessary further investigations not performed. This data will 
also be published as a separate study. 
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 It involves the taking of a blood sample (10ml /2 teaspoons blood) and a urine sample (100ml/ 
half a cup) from you. 
 
 If a monoclonal peak is present, you will be offered further investigations to rule out lymphoma 
or plasma cell tumours if necessary. This may involve X-rays, CT scan, bone marrow biopsy tests. 
This will be discussed with you and your consent obtained before proceeding with any further 
tests. The peak will also be followed up 6 monthly or yearly with a blood or urine sample. 
 
 All patients with HIV infection that are followed up at the Tygerberg infectious Diseases Clinic are 
invited to participate in this study. 
 
 The advantage of taking part in this study is that the presence of a monoclonal peak will be 
identified and followed up. 
 
 The risks involved in participation in this research study includes the normal risks of blood taking 
which includes 
- pain at the site of blood sampling 
- bleeding and haematoma formation at the site of injury. 
If further follow up investigations are necessary, the procedure and risks will be explained and 
consent taken before proceeding. 
 
 All information collected will be treated confidentially. It will be used in a publication and thesis, 
but the identity of participants will remain anonymous. Only the medical officers collecting the 
information and the researchers processing the information will have access to the information 
 
 Participation is voluntary and you are free to decline to participate. You are also free to withdraw 
from the study at any point, even if you had agreed to take part.  Participation in this study will 
not influence or change the treatment that you receive. 
 
 You will not be paid to participate in the study, but there will be no costs involved for you, if you 
do participate. 
 
 Any questions can be directed to the physician treating you. If more  information is required, the 
investigators can be contacted at the above numbers: 
 
Declaration by participant: 
 
I _____________________________________________________agree to participate in the research 
project titeld:  
Monoclonal gammopathy in patients with HIV: The prevalence and association with stage of disease, 
chronic antigen stimulation and the effect of HAART  
and 
A comparison of the sensitivity and specificity of agarose gel electrophoresis, capillary zone 
electrophoresis and serum free light chain analysis in the diagnosis of monoclonal gammopathy in 
patients with HIV. 
 
 
 I declare that I read the above information or that it was explained to me and that I understand 
it. 
 I had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to take 
part and that I may choose to leave the study at any time. 
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Signed at _______________________________on_____________________________ 
    
Signature of participant: ___________________ Witness:____________________________ 
 
 
 
 
 
 
 
Declaration by investigator: 
 
I _____________________________ declare that I explained the information in this document to the 
patient, encouraged him to ask questions and is satisfied that he understands all the aspects of this 
research project. 
 
Signed at _______________________________on_____________________________ 
 
Signature of researcher/ clinician:   _________________ Witness:_____________________ 
 
Declaration by translator (if used). 
 
I  __________________________ declare that I assisted the above named researcher to explain the 
information in Afrikaans / Xhosa (circle). 
 We encouraged him to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has his/her questions satisfactorily answered. 
 
Signed at _______________________________on_____________________________ 
     
Signature of translator:_____________________Witness: _______________________ 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM: 
CONTROL GROUP 
 
 
TITLE OF THE RESEARCH PROJECT 
Free Light Chains in patients with HIV: establishing local reference ranges and their 
association with stage of disease, chronic antigen stimulation and the effect of HAART 
 
PRINCIPAL INVESTIGATOR:   
Dr Annalise Zemlin 
  
CONTACT NUMBER: 
Office:  021 – 938 4854 / 9384107 
 
You are being invited to take part as a control (healthy individual) in a research project.   
Your participation is entirely voluntary and you are free to decline to participate.  If you 
say no, this will not affect you negatively in any way whatsoever.  You are also free to 
withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles 
of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
 
The project aims to determine the reference ranges of certain blood tests which will then be 
performed on patients infected with HIV to determine how they differ from the general 
population. For the study, we will need to test a small amount of your blood donated to the 
blood bank. No extra blood will be collected. No HIV test will be performed on this sample.  
Free light chains are part of antibody molecules which are produced by the body in response 
to inflammation. We know that HIV may lead to a change in the production of antibodies, 
but have no information about the levels of free light chains in the HIV-infected patient. To 
be able to evaluate the relevance of the results, we have to compare it with the presence / 
absence of these free light chains in healthy individuals. We will therefore conduct a study 
at Tygerberg Hospital.  Patients with advanced HIV infection have already enrolled in the 
study.  In a comparative group, blood from 121 healthy blood donors is also needed to 
complete the study. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a laboratory based 
research study entitled:  
 
Free Light Chains in patients with HIV: establishing local reference ranges and 
their association with stage of disease, chronic antigen stimulation and the effect 
of HAART 
  
I declare that: 
 
 I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 .........................................................   .......................................................  
Signature of participant Signature of witness 
 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 I did/did not use a translator.  
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 .........................................................   .......................................................  
Signature of investigator Signature of witness 
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Decleration by Interpreter  
 
I (name) ……………………………………………..……… declare that: 
 
 
 I have asisted the investigator (name)............................................to explain 
the information in this document in English/Xhosa to (name of participant) 
.................................................... 
 I have encouraged him / her to ask questions and had ample time to answer any 
questions. 
 I have given a factual version of what I was informed of 
 I am satisfied that the participant fully understands the contents of this 
document and that his / her questions were answered satisfactory. 
 
 
Signed at (place) ..............................…………….. on (date) …………....……….. 2010. 
 
 
 .........................................................   .......................................................  
Signature of interpreter  Signature of witness 
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Graphs obtained for the 95% reference intervals on the Mixed Ancestry population. 
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Graphs obtained for the 95% reference intervals on the Black population. 
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Correlation CD4+ count to kappa FLC
 Spearman r = -0.34 p=0.00
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Figure 6.1 Correlation of CD4+ count to  FLC 
 
Correlation CD4+ count to lambda FLC
 Spearman r = -0.34 p=0.00
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Figure 6.2 Correlation of CD4+ count to  FLC 
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Correlation CD4+ count to FLC ratio
 Spearman r = -0.07 p=0.18
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Figure 6.3 Correlation of CD4+ count to FLC ratio 
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Correlation duration of disease to kappa FLC
 Spearman r = -0.43 p=0.00
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Figure 7.1 Correlation of duration of disease to  FLC 
 
Correlation duration of disease to lambda FLC
 Spearman r = -0.35 p=0.00
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Figure 7.2 Correlation of duration of disease to  FLC 
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Correlation duration of disease to FLC ratio
 Spearman r = -0.10 p=0.05
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Figure 7.3 Correlation of duration of disease to FLC ratio 
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Correlation gamma fraction to kappa FLC
 Spearman r = 0.58 p=0.00
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Figure 8.1 Correlation of gamma fraction to  FLC 
 
Correlation of gamma fraction to lambda FLC
 Spearman r = 0.51 p=0.00
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Figure 8.2 Correlation of gamma fraction to  FLC 
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Correlation of gamma fraction to FLC ratio
 Spearman r = 0.24 p=0.00
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Figure 8.3 Correlation of gamma fraction to FLC ratio 
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Correlation of IgG levels to kappa FLC
 Spearman r = 0.66 p=0.00
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Figure 9.1 Correlation of IgG to  FLC 
Correlation of IgG levels to lambda FLC
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Figure 9.2 Correlation of IgG to  FLC 
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Correlation of IgG levels to FLC ratio
 Spearman r = 0.23 p=0.00
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Figure 9.3 Correlation of IgG to FLC ratio 
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Relationship between WHO stage of disease and kappa FLC
Current effect: F(3, 234)=2.0469, p=0.11 Kruskal-Wallis p=0.06
Vertical bars denote 0.95 confidence intervals
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Figure 10.1 Relationship between WHO stage of disease and  FLC 
 
 
Relationship between WHO stage of disease and lambda FLC
Current effect: F(3, 234)=4.1259, p=<0.01 Kruskal-Wall is p<0.01
Vertical bars denote 0.95 confidence intervals
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Figure 10.2 Relationship between WHO stage of disease and  FLC 
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Relationship between WHO stage of disease and FLC ratio
Current effect: F(3, 234)=1.1585, p=0.33 Kruskal-Wallis p=0.37
Vertical bars denote 0.95 confidence intervals
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Figure 10.3 Relationship between WHO stage of disease and FLC ratio 
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Relationship between ART use and kappa FLC
Current effect: F(1, 367)=75.516, p=<0.01 Mann-Whitney U p<0.01
Vertical bars denote 0.95 confidence intervals
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Figure 11.1 Relationship between ART use and  FLC 
 
 
 
Relationship between ART use and lambda FLC
Current effect: F(1, 367)=97.974, p=<0.01 Mann-Whitney U p<0.01
Vertical bars denote 0.95 confidence intervals
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Figure 11.2 Relationship between ART use and  FLC 
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Relationship between ART use and FLC ratio
Current effect: F(1, 367)=.38727, p=0.53 Mann-Whitney U p=0.98
Vertical bars denote 0.95 confidence intervals
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Figure 11.3 Relationship between ART use and FLC ratio 
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Realtionship between immunofixation for abnormal SPE and kappa FLC
Current effect: F(1, 366)=58.343, p=<0.01 Mann-Whitney U p<0.01
Vertical bars denote 0.95 confidence intervals
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Figure 12.1 Relationship between immunofixation for abnormal serum protein electrophoresis 
and  FLC 
Relationship between immunofixation for abnormal SPE and lambda FLC
Current effect: F(1, 366)=37.183, p=<0.01 Mann-Whitney U p<0.01
Vertical bars denote 0.95 confidence intervals
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Figure 12.2 Relationship between immunofixation for abnormal serum protein electrophoresis 
and  FLC 
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Relationship between immunofixation for abnormal SPE and FLC ratio
Current effect: F(1, 366)=17.611, p=<0.01 Mann-Whitney U p<0.01
Vertical bars denote 0.95 confidence intervals
n y
Immunofixation for abnormal SPE
0.25
0.26
0.27
0.28
0.29
0.30
0.31
0.32
lo
g1
0(
FL
C
R
)
 
Figure 12.3 Relationship between immunofixation for abnormal serum protein electrophoresis 
and FLC ratio 
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